ZA200305313B - Mikanolide derivatives, their preparation and therapeutic uses. - Google Patents
Mikanolide derivatives, their preparation and therapeutic uses. Download PDFInfo
- Publication number
- ZA200305313B ZA200305313B ZA200305313A ZA200305313A ZA200305313B ZA 200305313 B ZA200305313 B ZA 200305313B ZA 200305313 A ZA200305313 A ZA 200305313A ZA 200305313 A ZA200305313 A ZA 200305313A ZA 200305313 B ZA200305313 B ZA 200305313B
- Authority
- ZA
- South Africa
- Prior art keywords
- dimethyl
- dimethylamino
- trioxatetracyclo
- dioxodecahydro
- ene
- Prior art date
Links
- JRZGAAFGODYEEA-ATNXOXLHSA-N Mikanolide Chemical class C([C@]1([C@H]([C@@H]2O[C@@H]22)O1)C)[C@@H]1OC(=O)C(=C)[C@H]1[C@@H]1OC(=O)C2=C1 JRZGAAFGODYEEA-ATNXOXLHSA-N 0.000 title description 14
- 238000002360 preparation method Methods 0.000 title description 9
- 230000001225 therapeutic effect Effects 0.000 title description 3
- 150000001875 compounds Chemical class 0.000 claims description 179
- -1 nitro, hydroxy Chemical group 0.000 claims description 98
- 238000000034 method Methods 0.000 claims description 58
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims description 42
- 150000003839 salts Chemical class 0.000 claims description 39
- 125000000217 alkyl group Chemical group 0.000 claims description 33
- 125000003118 aryl group Chemical group 0.000 claims description 33
- 239000000203 mixture Substances 0.000 claims description 30
- 125000000623 heterocyclic group Chemical group 0.000 claims description 24
- 239000000126 substance Substances 0.000 claims description 21
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 19
- 201000010099 disease Diseases 0.000 claims description 18
- 125000004433 nitrogen atom Chemical group N* 0.000 claims description 18
- 239000003814 drug Substances 0.000 claims description 17
- 125000000753 cycloalkyl group Chemical group 0.000 claims description 15
- 229910052757 nitrogen Inorganic materials 0.000 claims description 15
- 125000005843 halogen group Chemical group 0.000 claims description 14
- 238000011282 treatment Methods 0.000 claims description 13
- 229910052799 carbon Inorganic materials 0.000 claims description 12
- 230000004663 cell proliferation Effects 0.000 claims description 11
- 125000001072 heteroaryl group Chemical group 0.000 claims description 11
- 125000003545 alkoxy group Chemical group 0.000 claims description 10
- 125000001188 haloalkyl group Chemical group 0.000 claims description 10
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims description 10
- 102000016928 DNA-directed DNA polymerase Human genes 0.000 claims description 9
- 108010014303 DNA-directed DNA polymerase Proteins 0.000 claims description 9
- 206010028980 Neoplasm Diseases 0.000 claims description 9
- 230000002159 abnormal effect Effects 0.000 claims description 9
- 125000001316 cycloalkyl alkyl group Chemical group 0.000 claims description 9
- 125000003710 aryl alkyl group Chemical group 0.000 claims description 7
- QERYCTSHXKAMIS-UHFFFAOYSA-M thiophene-2-carboxylate Chemical compound [O-]C(=O)C1=CC=CS1 QERYCTSHXKAMIS-UHFFFAOYSA-M 0.000 claims description 7
- DYSJMQABFPKAQM-UHFFFAOYSA-M 1-benzothiophene-2-carboxylate Chemical compound C1=CC=C2SC(C(=O)[O-])=CC2=C1 DYSJMQABFPKAQM-UHFFFAOYSA-M 0.000 claims description 6
- MLMQPDHYNJCQAO-UHFFFAOYSA-M 3,3-dimethylbutanoate Chemical compound CC(C)(C)CC([O-])=O MLMQPDHYNJCQAO-UHFFFAOYSA-M 0.000 claims description 6
- BBYDXOIZLAWGSL-UHFFFAOYSA-M 4-fluorobenzoate Chemical compound [O-]C(=O)C1=CC=C(F)C=C1 BBYDXOIZLAWGSL-UHFFFAOYSA-M 0.000 claims description 6
- CIUQDSCDWFSTQR-UHFFFAOYSA-N [C]1=CC=CC=C1 Chemical compound [C]1=CC=CC=C1 CIUQDSCDWFSTQR-UHFFFAOYSA-N 0.000 claims description 6
- WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 claims description 6
- NZNMSOFKMUBTKW-UHFFFAOYSA-M cyclohexanecarboxylate Chemical compound [O-]C(=O)C1CCCCC1 NZNMSOFKMUBTKW-UHFFFAOYSA-M 0.000 claims description 6
- 239000008194 pharmaceutical composition Substances 0.000 claims description 6
- IWDODGTURUZGMD-UHFFFAOYSA-N (2,5-dimethoxyphenyl)carbamic acid Chemical compound COC1=CC=C(OC)C(NC(O)=O)=C1 IWDODGTURUZGMD-UHFFFAOYSA-N 0.000 claims description 5
- SNUFWDHMKCYJRH-UHFFFAOYSA-N (2-ethoxyphenyl)carbamic acid Chemical compound CCOC1=CC=CC=C1NC(O)=O SNUFWDHMKCYJRH-UHFFFAOYSA-N 0.000 claims description 5
- GAIKMRZQIUTWPW-UHFFFAOYSA-N (2-methoxyphenyl) carbamate Chemical compound COC1=CC=CC=C1OC(N)=O GAIKMRZQIUTWPW-UHFFFAOYSA-N 0.000 claims description 5
- LHJGPYIVFSTNBM-UHFFFAOYSA-N (4-tert-butylphenyl)carbamic acid Chemical compound CC(C)(C)C1=CC=C(NC(O)=O)C=C1 LHJGPYIVFSTNBM-UHFFFAOYSA-N 0.000 claims description 5
- QAVSAAADWVRRHO-UHFFFAOYSA-N 1-benzothiophen-3-ylcarbamic acid Chemical compound C1=CC=C2C(NC(=O)O)=CSC2=C1 QAVSAAADWVRRHO-UHFFFAOYSA-N 0.000 claims description 5
- SMNDYUVBFMFKNZ-UHFFFAOYSA-M 2-furoate Chemical compound [O-]C(=O)C1=CC=CO1 SMNDYUVBFMFKNZ-UHFFFAOYSA-M 0.000 claims description 5
- SWKPKONEIZGROQ-UHFFFAOYSA-M 4-(trifluoromethyl)benzoate Chemical compound [O-]C(=O)C1=CC=C(C(F)(F)F)C=C1 SWKPKONEIZGROQ-UHFFFAOYSA-M 0.000 claims description 5
- DHMQDGOQFOQNFH-UHFFFAOYSA-M Aminoacetate Chemical compound NCC([O-])=O DHMQDGOQFOQNFH-UHFFFAOYSA-M 0.000 claims description 5
- BVKZGUZCCUSVTD-UHFFFAOYSA-L Carbonate Chemical compound [O-]C([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-L 0.000 claims description 5
- 208000030852 Parasitic disease Diseases 0.000 claims description 5
- 125000004414 alkyl thio group Chemical group 0.000 claims description 5
- 150000001413 amino acids Chemical class 0.000 claims description 5
- 125000004432 carbon atom Chemical group C* 0.000 claims description 5
- MNWFXJYAOYHMED-UHFFFAOYSA-N heptanoic acid Chemical compound CCCCCCC(O)=O MNWFXJYAOYHMED-UHFFFAOYSA-N 0.000 claims description 5
- ZCQPYIDWQYERKC-UHFFFAOYSA-N naphthalen-2-yl carbamate Chemical compound C1=CC=CC2=CC(OC(=O)N)=CC=C21 ZCQPYIDWQYERKC-UHFFFAOYSA-N 0.000 claims description 5
- LCPDWSOZIOUXRV-UHFFFAOYSA-N phenoxyacetic acid Chemical compound OC(=O)COC1=CC=CC=C1 LCPDWSOZIOUXRV-UHFFFAOYSA-N 0.000 claims description 5
- BSCCSDNZEIHXOK-UHFFFAOYSA-N phenyl carbamate Chemical compound NC(=O)OC1=CC=CC=C1 BSCCSDNZEIHXOK-UHFFFAOYSA-N 0.000 claims description 5
- FFVJAVUSCJCRPT-UHFFFAOYSA-N thiophen-2-yl acetate Chemical compound CC(=O)OC1=CC=CS1 FFVJAVUSCJCRPT-UHFFFAOYSA-N 0.000 claims description 5
- YNVOMSDITJMNET-UHFFFAOYSA-M thiophene-3-carboxylate Chemical compound [O-]C(=O)C=1C=CSC=1 YNVOMSDITJMNET-UHFFFAOYSA-M 0.000 claims description 5
- FJANNOJSTOGZHK-UHFFFAOYSA-N 1-adamantyl carbamate Chemical compound C1C(C2)CC3CC2CC1(OC(=O)N)C3 FJANNOJSTOGZHK-UHFFFAOYSA-N 0.000 claims description 4
- IODMEDPPCXSFLD-UHFFFAOYSA-N 5-nitrofuran-2-carboxylic acid Chemical compound OC(=O)C1=CC=C([N+]([O-])=O)O1 IODMEDPPCXSFLD-UHFFFAOYSA-N 0.000 claims description 4
- 125000004453 alkoxycarbonyl group Chemical group 0.000 claims description 4
- 230000001580 bacterial effect Effects 0.000 claims description 4
- 201000011510 cancer Diseases 0.000 claims description 4
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 claims description 4
- 230000003612 virological effect Effects 0.000 claims description 4
- HVFYCVXJFDELPD-UHFFFAOYSA-N (2-tert-butyl-6-methylphenyl)carbamic acid Chemical compound CC1=CC=CC(C(C)(C)C)=C1NC(O)=O HVFYCVXJFDELPD-UHFFFAOYSA-N 0.000 claims description 3
- 201000001320 Atherosclerosis Diseases 0.000 claims description 3
- 206010004446 Benign prostatic hyperplasia Diseases 0.000 claims description 3
- 101100516554 Caenorhabditis elegans nhr-5 gene Proteins 0.000 claims description 3
- 206010016654 Fibrosis Diseases 0.000 claims description 3
- 230000002401 inhibitory effect Effects 0.000 claims description 3
- 230000003287 optical effect Effects 0.000 claims description 2
- TWWDUBTUOZAQLB-UHFFFAOYSA-N (5-phenylthiophen-2-yl)carbamic acid Chemical compound S1C(NC(=O)O)=CC=C1C1=CC=CC=C1 TWWDUBTUOZAQLB-UHFFFAOYSA-N 0.000 claims 3
- 239000004480 active ingredient Substances 0.000 claims 2
- 230000004761 fibrosis Effects 0.000 claims 1
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 claims 1
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 69
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 57
- 229960001760 dimethyl sulfoxide Drugs 0.000 description 57
- 239000000843 powder Substances 0.000 description 53
- 239000000047 product Substances 0.000 description 52
- 150000003254 radicals Chemical class 0.000 description 39
- 230000015572 biosynthetic process Effects 0.000 description 37
- 238000003786 synthesis reaction Methods 0.000 description 37
- 239000000243 solution Substances 0.000 description 33
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 26
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 18
- 238000006243 chemical reaction Methods 0.000 description 17
- 210000004027 cell Anatomy 0.000 description 14
- UOQXZMNXWXQCJU-XMOWUHPBSA-N Dihydromikanolide Chemical compound C([C@H]1[C@H]2[C@H](C(O1)=O)C)[C@]1(C)O[C@H]1[C@@H]1O[C@@H]1C1=C[C@H]2OC1=O UOQXZMNXWXQCJU-XMOWUHPBSA-N 0.000 description 13
- UOQXZMNXWXQCJU-VUUDCVLBSA-N Dihydromikanolide Natural products O=C1[C@@H](C)[C@H]2[C@H]3OC(=O)C([C@H]4O[C@H]4[C@H]4[C@@](C)(O4)C[C@@H]2O1)=C3 UOQXZMNXWXQCJU-VUUDCVLBSA-N 0.000 description 13
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 12
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 9
- JRZGAAFGODYEEA-UHFFFAOYSA-N Mikanolid Natural products C12OC2C(O2)C2(C)CC2OC(=O)C(=C)C2C2OC(=O)C1=C2 JRZGAAFGODYEEA-UHFFFAOYSA-N 0.000 description 9
- 238000010348 incorporation Methods 0.000 description 9
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 8
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 8
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 7
- 239000002244 precipitate Substances 0.000 description 7
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 6
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 6
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 6
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 6
- 150000001721 carbon Chemical group 0.000 description 6
- 238000010586 diagram Methods 0.000 description 6
- 239000002904 solvent Substances 0.000 description 6
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 5
- 230000000694 effects Effects 0.000 description 5
- 230000005764 inhibitory process Effects 0.000 description 5
- 230000008018 melting Effects 0.000 description 5
- 238000002844 melting Methods 0.000 description 5
- WCYWZMWISLQXQU-UHFFFAOYSA-N methyl Chemical compound [CH3] WCYWZMWISLQXQU-UHFFFAOYSA-N 0.000 description 5
- PSHKMPUSSFXUIA-UHFFFAOYSA-N n,n-dimethylpyridin-2-amine Chemical compound CN(C)C1=CC=CC=N1 PSHKMPUSSFXUIA-UHFFFAOYSA-N 0.000 description 5
- 239000002773 nucleotide Substances 0.000 description 5
- 125000003729 nucleotide group Chemical group 0.000 description 5
- 239000012074 organic phase Substances 0.000 description 5
- 125000000168 pyrrolyl group Chemical group 0.000 description 5
- 239000000523 sample Substances 0.000 description 5
- BDFAOUQQXJIZDG-UHFFFAOYSA-N 2-methylpropane-1-thiol Chemical compound CC(C)CS BDFAOUQQXJIZDG-UHFFFAOYSA-N 0.000 description 4
- ROSDSFDQCJNGOL-UHFFFAOYSA-N Dimethylamine Chemical compound CNC ROSDSFDQCJNGOL-UHFFFAOYSA-N 0.000 description 4
- CSNNHWWHGAXBCP-UHFFFAOYSA-L Magnesium sulfate Chemical compound [Mg+2].[O-][S+2]([O-])([O-])[O-] CSNNHWWHGAXBCP-UHFFFAOYSA-L 0.000 description 4
- 241001473283 Mikania Species 0.000 description 4
- 239000002609 medium Substances 0.000 description 4
- 125000002757 morpholinyl group Chemical group 0.000 description 4
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 description 4
- 125000004193 piperazinyl group Chemical group 0.000 description 4
- 125000005936 piperidyl group Chemical group 0.000 description 4
- 125000000467 secondary amino group Chemical group [H]N([*:1])[*:2] 0.000 description 4
- 239000000377 silicon dioxide Substances 0.000 description 4
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 4
- 125000001544 thienyl group Chemical group 0.000 description 4
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 4
- WSLDOOZREJYCGB-UHFFFAOYSA-N 1,2-Dichloroethane Chemical compound ClCCCl WSLDOOZREJYCGB-UHFFFAOYSA-N 0.000 description 3
- IQFYYKKMVGJFEH-OFKYTIFKSA-N 1-[(2r,4s,5r)-4-hydroxy-5-(tritiooxymethyl)oxolan-2-yl]-5-methylpyrimidine-2,4-dione Chemical compound C1[C@H](O)[C@@H](CO[3H])O[C@H]1N1C(=O)NC(=O)C(C)=C1 IQFYYKKMVGJFEH-OFKYTIFKSA-N 0.000 description 3
- FPQQSJJWHUJYPU-UHFFFAOYSA-N 3-(dimethylamino)propyliminomethylidene-ethylazanium;chloride Chemical compound Cl.CCN=C=NCCCN(C)C FPQQSJJWHUJYPU-UHFFFAOYSA-N 0.000 description 3
- WFDIJRYMOXRFFG-UHFFFAOYSA-N Acetic anhydride Chemical compound CC(=O)OC(C)=O WFDIJRYMOXRFFG-UHFFFAOYSA-N 0.000 description 3
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 3
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 3
- VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 description 3
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 3
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 3
- AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical class CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 description 3
- KWYUFKZDYYNOTN-UHFFFAOYSA-M Potassium hydroxide Chemical compound [OH-].[K+] KWYUFKZDYYNOTN-UHFFFAOYSA-M 0.000 description 3
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 3
- 235000001014 amino acid Nutrition 0.000 description 3
- 229940024606 amino acid Drugs 0.000 description 3
- 239000003153 chemical reaction reagent Substances 0.000 description 3
- UAOMVDZJSHZZME-UHFFFAOYSA-N diisopropylamine Chemical compound CC(C)NC(C)C UAOMVDZJSHZZME-UHFFFAOYSA-N 0.000 description 3
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 3
- 238000001704 evaporation Methods 0.000 description 3
- 239000000284 extract Substances 0.000 description 3
- RAXXELZNTBOGNW-UHFFFAOYSA-N imidazole Natural products C1=CNC=N1 RAXXELZNTBOGNW-UHFFFAOYSA-N 0.000 description 3
- 239000012442 inert solvent Substances 0.000 description 3
- 239000007788 liquid Substances 0.000 description 3
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 3
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 3
- 230000035755 proliferation Effects 0.000 description 3
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 description 3
- 150000003335 secondary amines Chemical class 0.000 description 3
- 239000011780 sodium chloride Substances 0.000 description 3
- 238000013268 sustained release Methods 0.000 description 3
- 239000012730 sustained-release form Substances 0.000 description 3
- 150000003573 thiols Chemical class 0.000 description 3
- CKTSBUTUHBMZGZ-SHYZEUOFSA-N 2'‐deoxycytidine Chemical compound O=C1N=C(N)C=CN1[C@@H]1O[C@H](CO)[C@@H](O)C1 CKTSBUTUHBMZGZ-SHYZEUOFSA-N 0.000 description 2
- VHYFNPMBLIVWCW-UHFFFAOYSA-N 4-Dimethylaminopyridine Chemical compound CN(C)C1=CC=NC=C1 VHYFNPMBLIVWCW-UHFFFAOYSA-N 0.000 description 2
- 239000001729 Ammonium fumarate Substances 0.000 description 2
- CKTSBUTUHBMZGZ-UHFFFAOYSA-N Deoxycytidine Natural products O=C1N=C(N)C=CN1C1OC(CO)C(O)C1 CKTSBUTUHBMZGZ-UHFFFAOYSA-N 0.000 description 2
- WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 description 2
- 208000017604 Hodgkin disease Diseases 0.000 description 2
- 208000010747 Hodgkins lymphoma Diseases 0.000 description 2
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 2
- DCXYFEDJOCDNAF-REOHCLBHSA-N L-asparagine Chemical compound OC(=O)[C@@H](N)CC(N)=O DCXYFEDJOCDNAF-REOHCLBHSA-N 0.000 description 2
- CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 description 2
- AGPKZVBTJJNPAG-WHFBIAKZSA-N L-isoleucine Chemical compound CC[C@H](C)[C@H](N)C(O)=O AGPKZVBTJJNPAG-WHFBIAKZSA-N 0.000 description 2
- ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 description 2
- COLNVLDHVKWLRT-QMMMGPOBSA-N L-phenylalanine Chemical compound OC(=O)[C@@H](N)CC1=CC=CC=C1 COLNVLDHVKWLRT-QMMMGPOBSA-N 0.000 description 2
- OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 description 2
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 2
- AFVFQIVMOAPDHO-UHFFFAOYSA-M Methanesulfonate Chemical compound CS([O-])(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-M 0.000 description 2
- IQFYYKKMVGJFEH-XLPZGREQSA-N Thymidine Chemical compound O=C1NC(=O)C(C)=CN1[C@@H]1O[C@H](CO)[C@@H](O)C1 IQFYYKKMVGJFEH-XLPZGREQSA-N 0.000 description 2
- KZSNJWFQEVHDMF-UHFFFAOYSA-N Valine Natural products CC(C)C(N)C(O)=O KZSNJWFQEVHDMF-UHFFFAOYSA-N 0.000 description 2
- 239000002253 acid Substances 0.000 description 2
- 235000019297 ammonium fumarate Nutrition 0.000 description 2
- 150000008064 anhydrides Chemical class 0.000 description 2
- 239000003242 anti bacterial agent Substances 0.000 description 2
- 230000000844 anti-bacterial effect Effects 0.000 description 2
- 239000000010 aprotic solvent Substances 0.000 description 2
- 239000008346 aqueous phase Substances 0.000 description 2
- CKKXWJDFFQPBQL-SEPHDYHBSA-N azane;(e)-but-2-enedioic acid Chemical compound N.N.OC(=O)\C=C\C(O)=O CKKXWJDFFQPBQL-SEPHDYHBSA-N 0.000 description 2
- 125000000499 benzofuranyl group Chemical group O1C(=CC2=C1C=CC=C2)* 0.000 description 2
- 244000309466 calf Species 0.000 description 2
- 125000002837 carbocyclic group Chemical group 0.000 description 2
- 239000007822 coupling agent Substances 0.000 description 2
- OPTASPLRGRRNAP-UHFFFAOYSA-N cytosine Chemical compound NC=1C=CNC(=O)N=1 OPTASPLRGRRNAP-UHFFFAOYSA-N 0.000 description 2
- CKKXWJDFFQPBQL-UAIGNFCESA-N diazanium;(z)-but-2-enedioate Chemical compound [NH4+].[NH4+].[O-]C(=O)\C=C/C([O-])=O CKKXWJDFFQPBQL-UAIGNFCESA-N 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- QUPDWYMUPZLYJZ-UHFFFAOYSA-N ethyl Chemical compound C[CH2] QUPDWYMUPZLYJZ-UHFFFAOYSA-N 0.000 description 2
- 230000008020 evaporation Effects 0.000 description 2
- 239000012634 fragment Substances 0.000 description 2
- 125000002541 furyl group Chemical group 0.000 description 2
- 239000007903 gelatin capsule Substances 0.000 description 2
- ZDXPYRJPNDTMRX-UHFFFAOYSA-N glutamine Natural products OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 description 2
- 238000010438 heat treatment Methods 0.000 description 2
- 125000002768 hydroxyalkyl group Chemical group 0.000 description 2
- JMMWKPVZQRWMSS-UHFFFAOYSA-N isopropanol acetate Natural products CC(C)OC(C)=O JMMWKPVZQRWMSS-UHFFFAOYSA-N 0.000 description 2
- 229940011051 isopropyl acetate Drugs 0.000 description 2
- GWYFCOCPABKNJV-UHFFFAOYSA-N isovaleric acid Chemical compound CC(C)CC(O)=O GWYFCOCPABKNJV-UHFFFAOYSA-N 0.000 description 2
- 238000002372 labelling Methods 0.000 description 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
- 229910052943 magnesium sulfate Inorganic materials 0.000 description 2
- 235000019341 magnesium sulphate Nutrition 0.000 description 2
- 201000004792 malaria Diseases 0.000 description 2
- VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 2
- 239000012038 nucleophile Substances 0.000 description 2
- 230000000144 pharmacologic effect Effects 0.000 description 2
- 239000006187 pill Substances 0.000 description 2
- 210000002966 serum Anatomy 0.000 description 2
- HEMHJVSKTPXQMS-UHFFFAOYSA-M sodium hydroxide Inorganic materials [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 2
- 239000007787 solid Substances 0.000 description 2
- 210000002784 stomach Anatomy 0.000 description 2
- UCSJYZPVAKXKNQ-HZYVHMACSA-N streptomycin Chemical compound CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@@H]1[C@](C=O)(O)[C@H](C)O[C@H]1O[C@@H]1[C@@H](NC(N)=N)[C@H](O)[C@@H](NC(N)=N)[C@H](O)[C@H]1O UCSJYZPVAKXKNQ-HZYVHMACSA-N 0.000 description 2
- 239000003826 tablet Substances 0.000 description 2
- 125000001981 tert-butyldimethylsilyl group Chemical group [H]C([H])([H])[Si]([H])(C([H])([H])[H])[*]C(C([H])([H])[H])(C([H])([H])[H])C([H])([H])[H] 0.000 description 2
- 238000012360 testing method Methods 0.000 description 2
- 229940104230 thymidine Drugs 0.000 description 2
- 239000001226 triphosphate Substances 0.000 description 2
- UOCLXMDMGBRAIB-UHFFFAOYSA-N 1,1,1-trichloroethane Chemical compound CC(Cl)(Cl)Cl UOCLXMDMGBRAIB-UHFFFAOYSA-N 0.000 description 1
- IBMAYSYTZAVZPY-UHFFFAOYSA-N 1,7-dimethyl-4-propan-2-ylcyclodecane Chemical compound CC(C)C1CCC(C)CCCC(C)CC1 IBMAYSYTZAVZPY-UHFFFAOYSA-N 0.000 description 1
- IIVWHGMLFGNMOW-UHFFFAOYSA-N 2-methylpropane Chemical compound C[C](C)C IIVWHGMLFGNMOW-UHFFFAOYSA-N 0.000 description 1
- SLRMQYXOBQWXCR-UHFFFAOYSA-N 2154-56-5 Chemical compound [CH2]C1=CC=CC=C1 SLRMQYXOBQWXCR-UHFFFAOYSA-N 0.000 description 1
- ZCYVEMRRCGMTRW-UHFFFAOYSA-N 7553-56-2 Chemical group [I] ZCYVEMRRCGMTRW-UHFFFAOYSA-N 0.000 description 1
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 1
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- QGZKDVFQNNGYKY-UHFFFAOYSA-O Ammonium Chemical compound [NH4+] QGZKDVFQNNGYKY-UHFFFAOYSA-O 0.000 description 1
- 239000004475 Arginine Substances 0.000 description 1
- DCXYFEDJOCDNAF-UHFFFAOYSA-N Asparagine Natural products OC(=O)C(N)CC(N)=O DCXYFEDJOCDNAF-UHFFFAOYSA-N 0.000 description 1
- 208000035143 Bacterial infection Diseases 0.000 description 1
- DWRXFEITVBNRMK-UHFFFAOYSA-N Beta-D-1-Arabinofuranosylthymine Natural products O=C1NC(=O)C(C)=CN1C1C(O)C(O)C(CO)O1 DWRXFEITVBNRMK-UHFFFAOYSA-N 0.000 description 1
- WKBOTKDWSSQWDR-UHFFFAOYSA-N Bromine atom Chemical compound [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 description 1
- MQDFAHOAKURPPV-UHFFFAOYSA-N C12OC2(C)CC2OC(=O)C(C)C2C(OC2=O)CC2C(N(C)C)C1OC(=O)NC1(C2)CC(C3)CC2CC3C1 Chemical compound C12OC2(C)CC2OC(=O)C(C)C2C(OC2=O)CC2C(N(C)C)C1OC(=O)NC1(C2)CC(C3)CC2CC3C1 MQDFAHOAKURPPV-UHFFFAOYSA-N 0.000 description 1
- 101100294115 Caenorhabditis elegans nhr-4 gene Proteins 0.000 description 1
- 241000222122 Candida albicans Species 0.000 description 1
- ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 description 1
- KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 description 1
- 108020005199 Dehydrogenases Proteins 0.000 description 1
- 239000004375 Dextrin Substances 0.000 description 1
- 229920001353 Dextrin Polymers 0.000 description 1
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 1
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 241000588724 Escherichia coli Species 0.000 description 1
- WZKSXHQDXQKIQJ-UHFFFAOYSA-N F[C](F)F Chemical compound F[C](F)F WZKSXHQDXQKIQJ-UHFFFAOYSA-N 0.000 description 1
- PXGOKWXKJXAPGV-UHFFFAOYSA-N Fluorine Chemical compound FF PXGOKWXKJXAPGV-UHFFFAOYSA-N 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- 239000004471 Glycine Substances 0.000 description 1
- CPELXLSAUQHCOX-UHFFFAOYSA-N Hydrogen bromide Chemical compound Br CPELXLSAUQHCOX-UHFFFAOYSA-N 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical compound C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 description 1
- FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 description 1
- QIVBCDIJIAJPQS-VIFPVBQESA-N L-tryptophane Chemical compound C1=CC=C2C(C[C@H](N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-VIFPVBQESA-N 0.000 description 1
- KZSNJWFQEVHDMF-BYPYZUCNSA-N L-valine Chemical compound CC(C)[C@H](N)C(O)=O KZSNJWFQEVHDMF-BYPYZUCNSA-N 0.000 description 1
- JVTAAEKCZFNVCJ-UHFFFAOYSA-M Lactate Chemical compound CC(O)C([O-])=O JVTAAEKCZFNVCJ-UHFFFAOYSA-M 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- 206010057168 Leishmania infections Diseases 0.000 description 1
- 208000004554 Leishmaniasis Diseases 0.000 description 1
- ROHFNLRQFUQHCH-UHFFFAOYSA-N Leucine Natural products CC(C)CC(N)C(O)=O ROHFNLRQFUQHCH-UHFFFAOYSA-N 0.000 description 1
- 206010025323 Lymphomas Diseases 0.000 description 1
- 239000004472 Lysine Substances 0.000 description 1
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 244000101411 Micrechites serpyllifolius Species 0.000 description 1
- 244000153083 Mikania cordata Species 0.000 description 1
- 244000068786 Mikania scandens Species 0.000 description 1
- 208000034578 Multiple myelomas Diseases 0.000 description 1
- 229910002651 NO3 Inorganic materials 0.000 description 1
- NHNBFGGVMKEFGY-UHFFFAOYSA-N Nitrate Chemical compound [O-][N+]([O-])=O NHNBFGGVMKEFGY-UHFFFAOYSA-N 0.000 description 1
- 229910019142 PO4 Inorganic materials 0.000 description 1
- 206010061902 Pancreatic neoplasm Diseases 0.000 description 1
- 229930182555 Penicillin Natural products 0.000 description 1
- JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 1
- OAICVXFJPJFONN-UHFFFAOYSA-N Phosphorus Chemical compound [P] OAICVXFJPJFONN-UHFFFAOYSA-N 0.000 description 1
- 239000002202 Polyethylene glycol Substances 0.000 description 1
- ONIBWKKTOPOVIA-UHFFFAOYSA-N Proline Natural products OC(=O)C1CCCN1 ONIBWKKTOPOVIA-UHFFFAOYSA-N 0.000 description 1
- OFOBLEOULBTSOW-UHFFFAOYSA-N Propanedioic acid Natural products OC(=O)CC(O)=O OFOBLEOULBTSOW-UHFFFAOYSA-N 0.000 description 1
- 206010060862 Prostate cancer Diseases 0.000 description 1
- 208000000236 Prostatic Neoplasms Diseases 0.000 description 1
- MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 description 1
- 241000191967 Staphylococcus aureus Species 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 1
- AYFVYJQAPQTCCC-UHFFFAOYSA-N Threonine Natural products CC(O)C(N)C(O)=O AYFVYJQAPQTCCC-UHFFFAOYSA-N 0.000 description 1
- 239000004473 Threonine Substances 0.000 description 1
- 208000024770 Thyroid neoplasm Diseases 0.000 description 1
- YZCKVEUIGOORGS-NJFSPNSNSA-N Tritium Chemical compound [3H] YZCKVEUIGOORGS-NJFSPNSNSA-N 0.000 description 1
- QIVBCDIJIAJPQS-UHFFFAOYSA-N Tryptophan Natural products C1=CC=C2C(CC(N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-UHFFFAOYSA-N 0.000 description 1
- 239000006035 Tryptophane Substances 0.000 description 1
- 208000036142 Viral infection Diseases 0.000 description 1
- YUDRVAHLXDBKSR-UHFFFAOYSA-N [CH]1CCCCC1 Chemical compound [CH]1CCCCC1 YUDRVAHLXDBKSR-UHFFFAOYSA-N 0.000 description 1
- QJBKHULCDHLCMS-UHFFFAOYSA-N [O-]C(NC1=CC=C[S+]1C1=CC=CC=C1)=O Chemical compound [O-]C(NC1=CC=C[S+]1C1=CC=CC=C1)=O QJBKHULCDHLCMS-UHFFFAOYSA-N 0.000 description 1
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 1
- 125000002777 acetyl group Chemical group [H]C([H])([H])C(*)=O 0.000 description 1
- 239000013543 active substance Substances 0.000 description 1
- 235000004279 alanine Nutrition 0.000 description 1
- 230000001476 alcoholic effect Effects 0.000 description 1
- 150000001412 amines Chemical group 0.000 description 1
- 230000003698 anagen phase Effects 0.000 description 1
- 230000001093 anti-cancer Effects 0.000 description 1
- 239000002260 anti-inflammatory agent Substances 0.000 description 1
- 229940121363 anti-inflammatory agent Drugs 0.000 description 1
- 230000003110 anti-inflammatory effect Effects 0.000 description 1
- 230000000845 anti-microbial effect Effects 0.000 description 1
- 230000001028 anti-proliverative effect Effects 0.000 description 1
- 230000000259 anti-tumor effect Effects 0.000 description 1
- 229940088710 antibiotic agent Drugs 0.000 description 1
- 239000003443 antiviral agent Substances 0.000 description 1
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 1
- 235000009582 asparagine Nutrition 0.000 description 1
- 229960001230 asparagine Drugs 0.000 description 1
- 235000003704 aspartic acid Nutrition 0.000 description 1
- 208000022362 bacterial infectious disease Diseases 0.000 description 1
- 125000004196 benzothienyl group Chemical group S1C(=CC2=C1C=CC=C2)* 0.000 description 1
- PASDCCFISLVPSO-UHFFFAOYSA-N benzoyl chloride Chemical compound ClC(=O)C1=CC=CC=C1 PASDCCFISLVPSO-UHFFFAOYSA-N 0.000 description 1
- IQFYYKKMVGJFEH-UHFFFAOYSA-N beta-L-thymidine Natural products O=C1NC(=O)C(C)=CN1C1OC(CO)C(O)C1 IQFYYKKMVGJFEH-UHFFFAOYSA-N 0.000 description 1
- OQFSQFPPLPISGP-UHFFFAOYSA-N beta-carboxyaspartic acid Natural products OC(=O)C(N)C(C(O)=O)C(O)=O OQFSQFPPLPISGP-UHFFFAOYSA-N 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 210000000988 bone and bone Anatomy 0.000 description 1
- 210000000133 brain stem Anatomy 0.000 description 1
- 210000000481 breast Anatomy 0.000 description 1
- GDTBXPJZTBHREO-UHFFFAOYSA-N bromine Substances BrBr GDTBXPJZTBHREO-UHFFFAOYSA-N 0.000 description 1
- 229910052794 bromium Inorganic materials 0.000 description 1
- 239000007853 buffer solution Substances 0.000 description 1
- 125000000484 butyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 239000001506 calcium phosphate Substances 0.000 description 1
- 229910000389 calcium phosphate Inorganic materials 0.000 description 1
- 235000011010 calcium phosphates Nutrition 0.000 description 1
- 229940095731 candida albicans Drugs 0.000 description 1
- 239000001768 carboxy methyl cellulose Substances 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 235000010980 cellulose Nutrition 0.000 description 1
- 210000003169 central nervous system Anatomy 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 210000003679 cervix uteri Anatomy 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 239000000460 chlorine Substances 0.000 description 1
- 229910052801 chlorine Inorganic materials 0.000 description 1
- KOPOQZFJUQMUML-UHFFFAOYSA-N chlorosilane Chemical compound Cl[SiH3] KOPOQZFJUQMUML-UHFFFAOYSA-N 0.000 description 1
- 238000003776 cleavage reaction Methods 0.000 description 1
- 210000001072 colon Anatomy 0.000 description 1
- 208000029742 colonic neoplasm Diseases 0.000 description 1
- 238000004737 colorimetric analysis Methods 0.000 description 1
- 210000002808 connective tissue Anatomy 0.000 description 1
- 239000013068 control sample Substances 0.000 description 1
- 125000001995 cyclobutyl group Chemical group [H]C1([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 1
- 125000001511 cyclopentyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 1
- 125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 description 1
- 235000018417 cysteine Nutrition 0.000 description 1
- XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 description 1
- 230000009089 cytolysis Effects 0.000 description 1
- 229940104302 cytosine Drugs 0.000 description 1
- SUYVUBYJARFZHO-RRKCRQDMSA-N dATP Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@H]1C[C@H](O)[C@@H](COP(O)(=O)OP(O)(=O)OP(O)(O)=O)O1 SUYVUBYJARFZHO-RRKCRQDMSA-N 0.000 description 1
- SUYVUBYJARFZHO-UHFFFAOYSA-N dATP Natural products C1=NC=2C(N)=NC=NC=2N1C1CC(O)C(COP(O)(=O)OP(O)(=O)OP(O)(O)=O)O1 SUYVUBYJARFZHO-UHFFFAOYSA-N 0.000 description 1
- RGWHQCVHVJXOKC-SHYZEUOFSA-J dCTP(4-) Chemical compound O=C1N=C(N)C=CN1[C@@H]1O[C@H](COP([O-])(=O)OP([O-])(=O)OP([O-])([O-])=O)[C@@H](O)C1 RGWHQCVHVJXOKC-SHYZEUOFSA-J 0.000 description 1
- HAAZLUGHYHWQIW-KVQBGUIXSA-N dGTP Chemical compound C1=NC=2C(=O)NC(N)=NC=2N1[C@H]1C[C@H](O)[C@@H](COP(O)(=O)OP(O)(=O)OP(O)(O)=O)O1 HAAZLUGHYHWQIW-KVQBGUIXSA-N 0.000 description 1
- NHVNXKFIZYSCEB-XLPZGREQSA-N dTTP Chemical compound O=C1NC(=O)C(C)=CN1[C@@H]1O[C@H](COP(O)(=O)OP(O)(=O)OP(O)(O)=O)[C@@H](O)C1 NHVNXKFIZYSCEB-XLPZGREQSA-N 0.000 description 1
- 235000019425 dextrin Nutrition 0.000 description 1
- 229940043279 diisopropylamine Drugs 0.000 description 1
- 239000001177 diphosphate Substances 0.000 description 1
- XPPKVPWEQAFLFU-UHFFFAOYSA-J diphosphate(4-) Chemical compound [O-]P([O-])(=O)OP([O-])([O-])=O XPPKVPWEQAFLFU-UHFFFAOYSA-J 0.000 description 1
- 235000011180 diphosphates Nutrition 0.000 description 1
- 208000035475 disorder Diseases 0.000 description 1
- 238000004821 distillation Methods 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- 210000004696 endometrium Anatomy 0.000 description 1
- RIFGWPKJUGCATF-UHFFFAOYSA-N ethyl chloroformate Chemical compound CCOC(Cl)=O RIFGWPKJUGCATF-UHFFFAOYSA-N 0.000 description 1
- 210000001508 eye Anatomy 0.000 description 1
- 229910052731 fluorine Inorganic materials 0.000 description 1
- 239000011737 fluorine Substances 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- VZCYOOQTPOCHFL-OWOJBTEDSA-L fumarate(2-) Chemical class [O-]C(=O)\C=C\C([O-])=O VZCYOOQTPOCHFL-OWOJBTEDSA-L 0.000 description 1
- 239000001530 fumaric acid Substances 0.000 description 1
- 210000004211 gastric acid Anatomy 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- IBMAYSYTZAVZPY-QDMKHBRRSA-N germacrane Chemical compound CC(C)[C@H]1CC[C@@H](C)CCC[C@@H](C)CC1 IBMAYSYTZAVZPY-QDMKHBRRSA-N 0.000 description 1
- 229930001431 germacrane Natural products 0.000 description 1
- 235000013922 glutamic acid Nutrition 0.000 description 1
- 239000004220 glutamic acid Substances 0.000 description 1
- 150000002334 glycols Chemical class 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 125000004475 heteroaralkyl group Chemical group 0.000 description 1
- 125000005842 heteroatom Chemical group 0.000 description 1
- 125000004051 hexyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 description 1
- 210000005260 human cell Anatomy 0.000 description 1
- 150000002430 hydrocarbons Chemical group 0.000 description 1
- 150000003840 hydrochlorides Chemical class 0.000 description 1
- XMBWDFGMSWQBCA-UHFFFAOYSA-N hydrogen iodide Chemical compound I XMBWDFGMSWQBCA-UHFFFAOYSA-N 0.000 description 1
- 125000002883 imidazolyl group Chemical group 0.000 description 1
- 125000001041 indolyl group Chemical group 0.000 description 1
- 210000000936 intestine Anatomy 0.000 description 1
- 238000010255 intramuscular injection Methods 0.000 description 1
- 239000007927 intramuscular injection Substances 0.000 description 1
- 125000000959 isobutyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])* 0.000 description 1
- AGPKZVBTJJNPAG-UHFFFAOYSA-N isoleucine Natural products CCC(C)C(N)C(O)=O AGPKZVBTJJNPAG-UHFFFAOYSA-N 0.000 description 1
- 229960000310 isoleucine Drugs 0.000 description 1
- 125000001972 isopentyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])C([H])([H])* 0.000 description 1
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 210000000867 larynx Anatomy 0.000 description 1
- 208000032839 leukemia Diseases 0.000 description 1
- 239000002502 liposome Substances 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 210000004072 lung Anatomy 0.000 description 1
- 239000011777 magnesium Substances 0.000 description 1
- 229910052749 magnesium Inorganic materials 0.000 description 1
- 235000001055 magnesium Nutrition 0.000 description 1
- 235000019359 magnesium stearate Nutrition 0.000 description 1
- 239000011976 maleic acid Substances 0.000 description 1
- 150000002688 maleic acid derivatives Chemical class 0.000 description 1
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 201000001441 melanoma Diseases 0.000 description 1
- 229930182817 methionine Natural products 0.000 description 1
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 description 1
- 229920000609 methyl cellulose Polymers 0.000 description 1
- 239000001923 methylcellulose Substances 0.000 description 1
- 235000010981 methylcellulose Nutrition 0.000 description 1
- 150000007522 mineralic acids Chemical class 0.000 description 1
- 230000002438 mitochondrial effect Effects 0.000 description 1
- 230000002013 molluscicidal effect Effects 0.000 description 1
- 125000002950 monocyclic group Chemical group 0.000 description 1
- VMGAPWLDMVPYIA-HIDZBRGKSA-N n'-amino-n-iminomethanimidamide Chemical compound N\N=C\N=N VMGAPWLDMVPYIA-HIDZBRGKSA-N 0.000 description 1
- 125000001624 naphthyl group Chemical group 0.000 description 1
- 125000001971 neopentyl group Chemical group [H]C([*])([H])C(C([H])([H])[H])(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- 230000000269 nucleophilic effect Effects 0.000 description 1
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 1
- 150000007524 organic acids Chemical class 0.000 description 1
- 235000005985 organic acids Nutrition 0.000 description 1
- 239000003960 organic solvent Substances 0.000 description 1
- 210000001672 ovary Anatomy 0.000 description 1
- 125000002971 oxazolyl group Chemical group 0.000 description 1
- 229910052760 oxygen Inorganic materials 0.000 description 1
- 210000000496 pancreas Anatomy 0.000 description 1
- 201000002528 pancreatic cancer Diseases 0.000 description 1
- 208000008443 pancreatic carcinoma Diseases 0.000 description 1
- 229940049954 penicillin Drugs 0.000 description 1
- 125000001147 pentyl group Chemical group C(CCCC)* 0.000 description 1
- 230000010412 perfusion Effects 0.000 description 1
- 210000003800 pharynx Anatomy 0.000 description 1
- COLNVLDHVKWLRT-UHFFFAOYSA-N phenylalanine Natural products OC(=O)C(N)CC1=CC=CC=C1 COLNVLDHVKWLRT-UHFFFAOYSA-N 0.000 description 1
- 239000010452 phosphate Substances 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
- 229910052698 phosphorus Inorganic materials 0.000 description 1
- 239000011574 phosphorus Substances 0.000 description 1
- 230000001963 piscicidal effect Effects 0.000 description 1
- 229920001223 polyethylene glycol Polymers 0.000 description 1
- 229920006316 polyvinylpyrrolidine Polymers 0.000 description 1
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 210000002307 prostate Anatomy 0.000 description 1
- 125000006239 protecting group Chemical group 0.000 description 1
- 125000004076 pyridyl group Chemical group 0.000 description 1
- 125000000714 pyrimidinyl group Chemical group 0.000 description 1
- 238000011002 quantification Methods 0.000 description 1
- 230000002285 radioactive effect Effects 0.000 description 1
- 210000000664 rectum Anatomy 0.000 description 1
- BOLDJAUMGUJJKM-LSDHHAIUSA-N renifolin D Natural products CC(=C)[C@@H]1Cc2c(O)c(O)ccc2[C@H]1CC(=O)c3ccc(O)cc3O BOLDJAUMGUJJKM-LSDHHAIUSA-N 0.000 description 1
- 239000012047 saturated solution Substances 0.000 description 1
- 230000007017 scission Effects 0.000 description 1
- 125000002914 sec-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
- 229930004725 sesquiterpene Natural products 0.000 description 1
- 150000004354 sesquiterpene derivatives Chemical class 0.000 description 1
- 238000006884 silylation reaction Methods 0.000 description 1
- 210000003491 skin Anatomy 0.000 description 1
- 210000000813 small intestine Anatomy 0.000 description 1
- 235000019812 sodium carboxymethyl cellulose Nutrition 0.000 description 1
- 229920001027 sodium carboxymethylcellulose Polymers 0.000 description 1
- JUJBNYBVVQSIOU-UHFFFAOYSA-M sodium;4-[2-(4-iodophenyl)-3-(4-nitrophenyl)tetrazol-2-ium-5-yl]benzene-1,3-disulfonate Chemical compound [Na+].C1=CC([N+](=O)[O-])=CC=C1N1[N+](C=2C=CC(I)=CC=2)=NC(C=2C(=CC(=CC=2)S([O-])(=O)=O)S([O-])(=O)=O)=N1 JUJBNYBVVQSIOU-UHFFFAOYSA-M 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 229960005322 streptomycin Drugs 0.000 description 1
- 125000001424 substituent group Chemical group 0.000 description 1
- KDYFGRWQOYBRFD-UHFFFAOYSA-L succinate(2-) Chemical compound [O-]C(=O)CCC([O-])=O KDYFGRWQOYBRFD-UHFFFAOYSA-L 0.000 description 1
- 235000000346 sugar Nutrition 0.000 description 1
- 150000008163 sugars Chemical class 0.000 description 1
- 229910052717 sulfur Inorganic materials 0.000 description 1
- 229910021653 sulphate ion Inorganic materials 0.000 description 1
- 239000000829 suppository Substances 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 239000000454 talc Substances 0.000 description 1
- 229910052623 talc Inorganic materials 0.000 description 1
- 229940095064 tartrate Drugs 0.000 description 1
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- BCNZYOJHNLTNEZ-UHFFFAOYSA-N tert-butyldimethylsilyl chloride Chemical compound CC(C)(C)[Si](C)(C)Cl BCNZYOJHNLTNEZ-UHFFFAOYSA-N 0.000 description 1
- 210000001550 testis Anatomy 0.000 description 1
- 125000003831 tetrazolyl group Chemical group 0.000 description 1
- 125000000335 thiazolyl group Chemical group 0.000 description 1
- 125000005301 thienylmethyl group Chemical group [H]C1=C([H])C([H])=C(S1)C([H])([H])* 0.000 description 1
- BMWZMDDFCPGUSM-UHFFFAOYSA-N thiophene-2-carboxylic acid;hydrochloride Chemical compound Cl.OC(=O)C1=CC=CS1 BMWZMDDFCPGUSM-UHFFFAOYSA-N 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- JOXIMZWYDAKGHI-UHFFFAOYSA-M toluene-4-sulfonate Chemical compound CC1=CC=C(S([O-])(=O)=O)C=C1 JOXIMZWYDAKGHI-UHFFFAOYSA-M 0.000 description 1
- 230000000699 topical effect Effects 0.000 description 1
- 125000004306 triazinyl group Chemical group 0.000 description 1
- QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 1
- 229910052722 tritium Inorganic materials 0.000 description 1
- 229960004799 tryptophan Drugs 0.000 description 1
- 210000004881 tumor cell Anatomy 0.000 description 1
- OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 description 1
- 210000003932 urinary bladder Anatomy 0.000 description 1
- 239000004474 valine Substances 0.000 description 1
- 230000009385 viral infection Effects 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D493/00—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system
- C07D493/12—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system in which the condensed system contains three hetero rings
- C07D493/18—Bridged systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Veterinary Medicine (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Virology (AREA)
- Tropical Medicine & Parasitology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
Description
®
DERIVATIVES OF MIKANOLIDE, THEIR PREPARATION AND THEIR THERAPEUTIC USES
A subject of the invention is new derivatives of mikanolide, their preparation processes as well as their therapeutic uses, in particular as anticancerous, antibacterial and antiviral agents.
Tropical plants of the Mikania genus such as M. cordata, M. scandens or M. micrantha ® 5S are part of certain traditional pharmacopeia of India, South America and Central
America. Under the names of guaco, bejuco de finca, cepu, liane francois, matafinca, or also vedolin, the extracts of Mikania are used as antibiotics and anti-inflammatories.
Active substances originating from extracts of Mikania have been isolated and characterized: these are mikanolide and dihydromikanolide (see their structures in the figure below), and to a lesser extent scandenolides. These are sesquiterpenes of the germacrane family, i.e. having 4-isopropyl-1,7-dimethylcyclodecane as a hydrocarbon skeleton (Herz et al., Tetrahedron Lett. (1967) 3111-3115; Kiang et al., Phytochemistry (1968) 7: 1035-1037; Cuenca et al., J. Nat. Prod. (1988), 51, 625-626). ow o Me o_o Me "0 \ “0 ® SE) SE) 74 0 NN 0 mikanolide dihydromikanolide
Studies of the extracts of Mikania report an antimicrobial activity against
Staphylococus aureus and Candida albicans (Facey et al., J. Pharm. Pharmacol. (1999) 51, 1455-1460; Mathur et al., Rev. Latinoam. Quim. (1975), 6, 201-205). Molluscicidal, piscicidal and bactericidal activities have also been described for dihydromikanolide (Vasquez et al., AG Meeting, Amsterdam, Netherlands, 26-30 July 1999, poster No.
_ .
For the purpose of elucidating structures, certain simple derivatives of mikanolide and dihydromikanolide, and in particular the compounds of general formulae (A1) and (A2) represented below
OR
0 Me oR fle \ “0 \ 0 @) 0 O 0)
Oo Oo ® (AD) (A2) in which R represents a hydrogen atom or the acetyl group, have been synthesized and described in Herz et al., J Org. Chem. (1970), 35, 1453-1464. However, no pharmacological activity has been disclosed for these compounds.
The Applicant recently described in PCT Patent Application WO 01/39720 that mikanolide and dihydromikanolide are endowed with an antiproliferative activity linked to the inhibition of DNA-polymerase. However, mikanolides do not possess all the physico-chemical properties desirable for medicamentous use as they are neither very water soluble, nor very stable, which renders their pharmaceutical use relatively difficult, in particular in injectable form.
The Applicant has now developed new semi-synthetic mikanolide derivatives, which can be used for the treatment of diseases due to abnormal cell proliferation, in particular ® 15 for the treatment of cancer, viral diseases and bacterial and parasitic infections. These compounds have the advantage of better solubility and better stability than that of mikanolide and dihydromikanolide while retaining an activity similar to or even greater than that of the latter.
® i.
A subject of the invention is the compounds of general formula (I) 0 Ve
L Pe 0 0) 0)
Oo
R,
D
® corresponding to general sub-formulae (I); and (I);
R
3
R.... : < : < 2 0 0
Oo 0 Oo o
Oo Oo
R, R, (Dn D2 in which ® R| represents a hydrogen atom or an SR4 or NR4Rs radical; 5 Ros represents SRg or NR¢R7.
Rj represents OH, O(CO)R 4, OSiR;5R sR 7, O(CO)OR 5 or O(CO)NHR js;
Rs and Re represent, independently, an alkyl radical, a cycloalkyl, cycloalkylalkyl, hydroxyalkyl radical or also one of the aryl or aralkyl radicals optionally substituted on their aryl group by one or more radicals chosen from the alkyl, hydroxy or alkoxy radicals,
Rs and R; represent, independently, a hydrogen atom, an alkyl radical, a cycloalkyl, cycloalkylalkyl, hydroxyalkyl radical or also one of the aryl or aralkyl radicals
® optionally substituted on their aryl group by one or more radicals chosen from the alkyl, hydroxy or alkoxy radicals,
R4 and Rs being able to form together with the nitrogen atom which carries them a heterocycle with 5 to 7 members, the additional members being chosen from the -CRgRg-, -NR¢-, -O- and -S- radicals, it being understood however that it there can only be one member chosen from -O- or -S- in said heterocycle, and Rg and R; being able to form together with the nitrogen atom which carries them a heterocycle with 5 to 7 members, the additional members being chosen from the -CR;1R};-, -NR3-, -O- and -S- radicals, it being understood however that there can only be one member chosen from -O- or -S- in said heterocycle,
Rs, Ryo, Ry; and R;; represent, independently each time they are involved, a hydrogen atom or an alkyl, alkoxycarbonyl or aralkyl radical, ® Ry and Ry; representing, independently each time they are involved, a hydrogen atom or each of Rg and Rj; being able to form respectively together with Rg and Ry; an -O-(CH)»-O- radical attached on either side to the carbon atom which carries them, such a radical only being present however once at most per NR4Rs or NR¢R; radical, represent, independently each time they are involved, a hydrogen atom or an alkyl radical;
Ris represents an alkyl, cycloalkyl or adamantyl radical or one of the aryl, heteroaryl, aralkyl or heteroaralkyl radicals optionally substituted on their aryl or heteroaryl group by one or more radicals chosen from a halogen atom and the alkyl, haloalkyl, nitro, hydroxy, alkoxy, alkylthio or phenyl radicals, or also Ris is such that Rj4~-COOH represents a natural amino acid or the optical ® enantiomer of such an amino acid;
Ris, Rig and Ry7 represent, independently, an alkyl radical or a phenyl radical,
Ris represents an alkyl, cycloalkyl or adamanty! radical or one of the aryl, heteroaryl, aralkyl or heteroaralkyl radicals optionally substituted on their aryl or heteroaryl group by one or more radicals chosen from a halogen atom and the alkyl, haloalkyl, nitro, hydroxy, alkoxy, alkylthio or phenyl radicals; it being understood however that when the compounds correspond to general sub- formula (I);, then R; does not represent a hydrogen atom; or the salts of the latter.
_ ® N
By alkyl, unless otherwise specified, is meant a linear or branched alkyl radical containing 1 to 12 carbon atoms, and preferably 1 to 6 carbon atoms. By cycloalkyl, unless otherwise specified, is meant a monocyclic carbon system containing 3 to 7 carbon atoms. By haloalkyl, is meant an alkyl radical at least one of the hydrogen atoms (and optionally all) of which is replaced by a halogen atom. By carbocyclic or heterocyclic aryl, unless otherwise specified, is meant a carbocyclic or heterocyclic system comprising one to three condensed rings at least one of which is an aromatic ring, a system being referred to as heterocyclic when at least one of the rings comprising it contains one or more heteroatoms (O, N or S). By aryl, unless otherwise specified, is meant a carbocyclic aryl radical. By heteroaryl is meant a heterocyclic aryl radical. By haloalkyl, is meant an alkyl radical at least one of the hydrogen atoms (and optionally all) of which is replaced by a halogen atom. Finally, by halogen atom is ® meant the fluorine, chlorine, bromine or iodine atoms.
By alkoxy, hydroxyalkyl, cycloalkylalkyl, aralkyl and heteroaralkyl radicals, is meant respectively the alkoxy, hydroxyalkyl, cycloalkylalkyl and aralkyl radicals the alkyl, cycloalkyl, aryl and heteroaralkyl radicals of which have the meanings indicated previously.
By natural amino acid, is understood valine (Val), leucine (Leu), isoleucine (Ile), methionine (Met), phenylalanine (Phe), asparagine (Asn), glutamic acid (Glu), glutamine (Gln), histidine (His), lysine (Lys), arginine (Arg), aspartic acid (Asp), glycine (Gly), alanine (Ala), serine (Ser), threonine (Thr), tyrosine (Tyr), tryptophane (Trp), cysteine (Cys) or proline (Pro).
By linear or branched alkyl having 1 to 6 carbon atoms, is meant in particular the ® methyl, ethyl, propyl, isopropyl, butyl, isobutyl, sec-butyl and tert-butyl, pentyl, neopentyl, isopentyl, hexyl, isohexyl radicals. By alkoxy, is meant in particular the methoxy, ethoxy and isopropoxy radicals, and in particular the methoxy and ethoxy radicals. By cycloalkyl is meant in particular the cyclopropyl, cyclobutyl, cyclopentyl and cyclohexyl radicals. By haloalkyl is meant in particular the trifluoromethyl radical.
By carbocyclic aryl is meant in particular the phenyl, naphthyl and phenanthryl radicals, preferably the phenyl and naphthyl radicals and more preferentially the phenyl radical. By heterocyclic aryl is meant in particular the pyrrolyl, furanyl, benzofuranyl, thienyl, benzothienyl, pyridyl, pyrimidinyl, triazinyl, imidazolyl, oxazolyl, thiazolyl, indolyl and quinolyl radicals, and preferably the furanyl, benzofuranyl, thienyl and benzothienyl radicals. By aralkyl is meant in particular a phenalkyl radical, and preferably the benzyl radical. By heteroaralkyl is meant in particular a thienylalkyl, furanylalkyl, pyrrolylalkyl and thiazolylalkyl radical (the alkyl radical of said radicals
® 6 being preferably a methyl radical), and preferably a thienylalkyl radical (preferably thienylmethyl).
A compound of general formula (I) having at least one of the following characteristics is preferred: eo the compound corresponds to general sub-formula (I); e R, represents a hydrogen atom or an NR4Rs radical; eR; represents an NR¢R7 radical. ® Rjrepresents OH, or an O(CO)R,4, OSiRsRisR;7 or O(CO)NHR 5 radical. ® More preferentially, a compound of general formula (I) will be such that it has at least one of the following characteristics: e the compound corresponds to general sub-formula (I);; e R; represents a hydrogen atom; eR; represents an NRgR7 radical. ® Rjrepresents AN O(CO)R 4, OSiR sR 6R 7 or O(CO)NHR 5 radical.
Quite particularly, a compound of general formula (I) is such that it has at least one of the following characteristics: e the compound corresponds to general sub-formula (I); _ eR; represents a hydrogen atom; eR; represents an NRsR~ radical and preferably an NRgR~ radical in which Rg and R- are chosen independently from a hydrogen atom and an alkyl radical; * Rjrepresents an O(CO)Ry4, OSiR sR R17 or O(CO)NHR 4 radical.
Moreover, R> will quite preferentially represent an NR¢R;radical in which Rg and
Rare alkyl radicals, and in particular an NR¢R; radical in which Rg and Ry are methyl radicals. R3 will quite preferentially represent an O(CO)NHR (5 radical.
Preferably also, Rs will represent an alkyl or aralkyl radical, and Rs will represent a hydrogen atom or an alkyl radical, or also Ry and Rs will form together with the nitrogen atom which carries them a heterocycle with 5 to 7 members, the additional
_ ® . members being chosen from the -CRsRo-, -NRo-, -O- and -S- radicals. Preferably, Rs will represent, independently each time it is involved, a hydrogen atom or an alkyl radical (and preferably a hydrogen atom) and Rg will represent, independently each time it is involved, a hydrogen atom. Preferably, Ro will represent, independently each time it is involved, a hydrogen atom or an alkyl radical.
Preferably also, Re will represent an alkyl or aralkyl radical, and R; will represent a hydrogen atom or an alkyl radical, or also Rs and R; will form together with the nitrogen atom which carries them a heterocycle with 5 to 7 members, the additional members being chosen from the -CR;R2-, -NR3-, -O- and -S- radicals. Preferably, Ry; will represent, independently each time it is involved, a hydrogen atom or an alkyl or alkoxycarbonyl radical (and preferably a hydrogen atom) or also Rj; and Rj; will ® represent, once together, an -O-(CH;),-O- radical attached on either side to the carbon atom which carries it. Preferably, Ri; will represent, independently each time it is involved, a hydrogen atom or an alkyl radical.
Moreover, Ry4 will preferably represent an alkyl or cycloalkyl radical, or one of the aryl or heteroaryl radicals optionally substituted by a halogen atom or a haloalkyl or phenyl radical. More preferentially, Rs will represent a cycloalkyl radical or one of the aryl or heteroaryl radicals optionally substituted by a halogen atom or a haloalkyl radical. In a more preferred manner, Ri4 will represent a cyclohexyl radical or one of the phenyl, thienyl or benzothienyl radicals optionally substituted by a halogen atom.
Finally, Ris, Ris and Ry; will preferably represent alkyl radicals. In a particularly preferred manner, one of the Ris, Ris and R radicals will represent a tert-butyl radical and the other two will represent methyl radicals. ® Finally, Rig will preferably represent an alkyl, cycloalkyl or adamantyl radical, or one of the aryl or heteroaryl radicals optionally substituted by a halogen atom or an alkyl, haloalkyl, alkoxy, alkylthio or phenyl radical. More preferentially, Rg will represent a cycloalkyl radical or one of the aryl or heteroaryl radicals optionally substituted by an alkyl, alkoxy or alkylthio radical. Still more preferably, Rs will represent one of the phenyl, thienyl or benzothienyl radicals optionally substituted by an alkyl, alkoxy or alkylthio radical.
Moreover, when Rs and Rs form together with the nitrogen atom which carries them a heterocycle with 5 to 7 members, the NR4Rs radical preferably represents one of the pyrrolyl, piperidyl, piperazinyl, morpholinyl or thiomorpholinyl radicals optionally substituted by an alkyl radical (the latter being preferably a methyl or ethyl radical, and more preferentially a methyl radical) on one of its carbon or nitrogen atoms, or by an
® N -0-(CH;),-O- radical attached on either side to a carbon atom. More preferentially, when Ry and Rs form together with the nitrogen atom which carries them a heterocycle with 5 to 7 members, the NR4Rs radical will represent one of the pyrrolyl, piperidyl, piperazinyl, morpholinyl or thiomorpholinyl radicals optionally substituted by an alkyl radical (the latter being preferably a methyl radical) on one of its carbon or nitrogen atoms.
Similarly, when Rs and Ry; form together with the nitrogen atom which carries them a heterocycle with 5 to 7 members, the NRgR7 radical preferably represents one of the pyrrolyl, piperidyl, piperazinyl, morpholinyl or thiomorpholinyl radicals optionally substituted by an alkyl radical (the latter preferably being a methyl or ethyl radical, and more preferentially a methyl radical) on one of its carbon or nitrogen atoms, or by an ® -O-(CH;),-O- radical attached on either side to a carbon atom. More preferentially, when Rg and R7 form together with the nitrogen atom which carries them a heterocycle with 5 to 7 members, the NR¢R; radical will represent one of the pyrrolyl, piperidyl, piperazinyl, morpholinyl or thiomorpholinyl radicals optionally substituted by an alkyl radical (the latter preferably being a methyl radical) on one of its carbon or nitrogen atoms.
The invention relates in particular to the following compounds described in the examples: - 12-diisopropylaminomethyl-7-methyl-3,6, 10, 15-tetraoxapentacyclo [12.2.1.0%*.0°7.0°*Jheptadec-1(17)-ene-11, 16-dione; - 12-dimethylamino-3-dimethylaminomethyl-11-hydroxy-8-methyl- ® 5,9,15-trioxatetracyclo[ 11.2.1 .0%.0*'%Thexadec- 13(16)-ene-4,14-dione; - 12-benzyl(methyl)amino-3-benzyl(methyl)aminomethyl-11-hydroxy-8-methyl- 5,9,15-trioxatetracyclo[11.2.1.0%®.0%'*Jhexadec-13(16)-ene-4, 14-dione; - 11-hydroxy-8-methyl-12-morpholino-3-morpholinomethyl- 5,9,15-trioxatetracyclof 11.2.1 .0%.0%'%Jhexadec- 13(16)-ene-4,14-dione; - 12-dimethylamino-11-hydroxy-3,8-dimethyl- 5,9,15-trioxatetracyclo[ 11.2.1 .076.0*"Jhexadec- 13(16)-ene-4,14-dione; - 11-hydroxy-3,8-dimethyl-12-(4-methylpiperidino)- 5,9,15-trioxatetracyclo[11.2.1.0%%.0%'*Jhexadec-13(16)-ene-4, 14-dione; - 11-hydroxy-3,8-dimethyl-12-pyrrolidino- 5,9,15-trioxatetracyclo[ 11.2.1 02.0% hexadec- 13(16)-ene-4,14-dione;
® nN
- ethyl 1-[11-hydroxy-3,8-dimethyl-4,14-dioxo- 5,9,15-trioxatetracyclo[11.2.1 .0%%.0%'%Thexadec- 13(16)-en-12-yl]- 4-piperidinecarboxylate; - 12-(4-benzylpiperidino)-11-hydroxy-3,8-dimethyl-
5,9,15-trioxatetracyclo[11.2.1.0*°.0%'%Jhexadec-13(16)-ene-4, 14-dione; - 11-hydroxy-3,8-dimethyl-12-piperidino- 5,9,15-trioxatetracyclo[11.2.1.0*®.0%!%|hexadec-13(16)-ene-4, 14-dione; - 12-(1,4-dioxa-8-azaspiro[4.5]dec-8-yl)-11-hydroxy-3,8-dimethyl- 5,9,15-trioxatetracyclo[ 11.2.1 02°.0%!%Thexadec- 13(16)-ene-4,14-dione;
- 11-hydroxy-3,8-dimethyl-12-morpholino-
® 5,9,15-trioxatetracyclo[ 11.2.1.0*.0%'%Jhexadec-13(16)-ene-4,14-dione; - 11-(tert-butyldimethylsiloxy)-12-dimethylamino-3,8-dimethyl- 5,9,15-trioxatetracyclof[11.2.1.0*.0*'°Jhexadec-13(16)-ene-4, 14-dione; - 3,8-dimethyl-12-(4-methylpiperidino)-4,14-dioxo-
5,9,15-trioxatetracyclo[11.2.1 .07°.0*'"Jhexadec- 13(16)-en-11-yl acetate;
- 3,8-dimethyl-12-(4-methylpiperidino)-4,14-dioxo-1 1-phenylcarbonyloxy- 5,9,15-trioxatetracyclo[ 11.2.1 076.0%!" hexadec- 13(16)-ene;
- ethyl 3,8-dimethyl-12-(4-methylpiperidino)-4,14-dioxo- 5,9,15-trioxatetracyclo[ 11.2.1 .026.0%'%Thexadec-1 3(16)-en-11-yl carbonate;
- l1-hydroxy-12-isobutylsulphanyl-3-isobutylsulphanylmethyl-8-methyl- 5,9,15-trioxatetracyclo[11.2.1.0*°.0%'*Jhexadec-13(16)-ene-4, 14-dione;
- 11-hydroxy-12-isobutylsulphanyl-3,8-dimethyl- ® 5,9,15-trioxatetracyclo[11.2.1.0%%.0*'“]hexadec-13(16)-ene-4,14-dione; - 12-(dimethylamino)-3,8-dimethyl-4,14-dioxo-
5,9,15-trioxatetracyclo[11.2.1.0%°.0*'*Jhexadec-13(16)-en-11-yl benzoate; - 12-(dimethylamino)-3,8-dimethyl-4,14-dioxo- 5,9,15-trioxatetracyclo[11.2.1.0%°.0*'"|hexadec-13(16)-en-11-yl acetate;
- 12-(dimethylamino)-3,8-dimethyl-4,14-dioxo- 5,9,15-trioxatetracyclo[ 11.2.1.0%%.0%!°hexadec-13(16)-en-11-yl cyclohexanecarboxylate;
- 12-(dimethylamino)-3,8-dimethyl-4,14-dioxo- 5,9,15-trioxatetracyclo[11.2.1 .07.0%'%hexadec-1 3(16)-en-11-yl 4-fluorobenzoate;
® 0. - 12-(dimethylamino)-3,8-dimethyl-4,14-dioxo- 5,9,15-trioxatetracyclo[11.2.1 02.0%" hexadec- 13(16)-en-11-yl heptanoate; - 12-(dimethylamino)-3,8-dimethyl-4,14-dioxo- 5,9,15-trioxatetracyclo[11.2.1.0%%.0%'%|hexadec-13(16)-en-11-yl 4- (trifluoromethyl)benzoate; - 12-(dimethylamino)-3,8-dimethyl-4,14-diox0-5,9,15- trioxatetracyclo[11.2.1.0%°.0*'*Jhexadec-13(16)-en-11-yl 2-thiophenecarboxylate; - 12-(dimethylamino)-3,8-dimethyl-4,14-diox0-5,9,15- trioxatetracyclo[11.2.1 0° $ 0%'%hexadec- 13(16)-en-11-yl 3,3-dimethylbutanoate;
- 12-(dimethylamino)-3,8-dimethyl-4,14-diox0-5,9,15-
@® trioxatetracyclo[11.2.1 036.0%! %hexadec-1 3(16)-en-11-yl 1-benzothiophene-2- carboxylate; - 12-(dimethylamino)-3,8-dimethyl-4,14-diox0-5,9,15- trioxatetracyclo[11.2.1.0%%.0%'*Jhexadec-13(16)-en-11 -yl 2-furoate;
- 12-(dimethylamino)-3,8-dimethyl-4,14-diox0-5,9,15- trioxatetracyclo[11.2.1 .07%.0%'%hexadec-1 3(16)-en-11-yl 5-nitro-2-furoate;
- 12-(dimethylamino)-3,8-dimethyl-4,14-dioxo- 5,9,15-trioxatetracyclo[11.2.1.0%°.0*'*Jhexadec-13(16)-en-11 -yl 2-thienylacetate; - 12-(dimethylamino)-3,8-dimethyl-4,14-dioxo-
5,9,15-trioxatetracyclo[11.2.1.0%%.0*'°|hexadec-13(16)-en-11 -yl phenoxyacetate; - 8-(dimethylamino)-3,10a -dimethyl-2,6-dioxodecahydro-4,7-methenofuro[3,2- c]oxireno[f]oxacycloundecin-9-yl 4-tert-butylphenylcarbamate;
@® - 8-(dimethylamino)-3,10a -dimethyl-2,6-dioxodecahydro- 4,7-methenofuro[3,2-c]oxireno[floxacycloundecin-9-yl thien-2-ylcarbamate;
- 8-(dimethylamino)-3,10a -dimethyl-2,6-dioxodecahydro-4,7-methenofurof3,2- c]oxireno[fJoxacycloundecin-9-yl 2-methoxyphenylcarbamate;
- 8-(dimethylamino)-3,10a -dimethyl-2,6-dioxodecahydro-4,7-metheno-furo{3,2- cJoxireno[f]oxacycloundecin-9-yl 2(methylthio)phenylcarbamate; - 8-(dimethylamino)-3,10a -dimethyl-2,6-dioxodecahydro-4,7-methenofuro[3,2-
cJoxireno[fJoxacycloundecin-9-yl 2-ethoxyphenylcarbamate;
- 8-(dimethylamino)-3,10a -dimethyl-2,6-dioxodecahydro-4,7-methenofuro[3,2- cJoxireno[f]oxacycloundecin-9-yl thien-3-ylcarbamate;
® . - 8-(dimethylamino)-3,10a -dimethyl-2,6-dioxodecahydro-4,7-methenofuro[3,2- c]oxireno[floxacycloundecin-9-yl 1-benzothien-3-ylcarbamate; - 8-(dimethylamino)-3,10a -dimethyl-2,6-dioxodecahydro-4,7-metheno-furo[3,2- cJoxireno[floxacycloundecin-9-yl N-(ter-butoxycarbonyl)glycinate; -8-(dimethylamino)-3,10a -dimethyl-2,6-dioxodecahydro-4,7-methenofuro[3,2- cloxireno[f]Joxacycloundecin-9-yl thien-3-ylacetate; - 8-(dimethylamino)-3,10a -dimethyl-2,6-dioxodecahydro-4,7-methenofuro[3,2- cJoxireno[fJoxacycloundecin-9-yl 1-benzothien-3-ylacetate; - 8-(dimethylamino)-3,10a -dimethyl-2,6-dioxodecahydro-4,7-methenofuro[3,2- cloxireno[f]oxacycloundecin-9-yl thiophene-3-carboxylate; ® - 8-(dimethylamino)-3,10a -dimethyl-2,6-dioxodecahydro-4,7-methenofuro[3,2- cJoxireno[f]loxacycloundecin-9-yl 5S-phenylthien-2-ylcarbamate; - 8-(dimethylamino)-3,10a -dimethyl-2,6-dioxodecahydro-4,7-methenofuro[3,2- cJoxireno[fJoxacycloundecin-9-yl 1-adamantylcarbamate; - 8-(dimethylamino)-3,10a -dimethyl-2,6-dioxodecahydro- 4,7-methenofuro[3,2-cJoxireno[f]oxacycloundecin-9-yl 2-naphthylcarbamate; - 8-(dimethylamino)-3,10a -dimethyl-2,6-dioxodecahydro-4,7-metheno-furo[3,2- cJoxireno[f]Joxacycloundecin-9-yl 2-tert-butyl-6-methylphenylcarbamate; - 8-(dimethylamino)-3,10a -dimethyl-2,6-dioxodecahydro-4,7-metheno-furo[3,2- c]oxirenoff]oxacycloundecin-9-yl 2,5-dimethoxyphenylcarbamate; as well as their salts.
C The invention quite particularly relates to the following compounds: - 12-dimethylamino-11-hydroxy-3,8-dimethyl- 5,9,15-trioxatetracyclo[11.2.1.0%®.0%'*Jhexadec-1 3(16)-ene-4,14-dione; - 11-(tert-butyldimethylsiloxy)-12-dimethylamino-3,8-dimethyl- 5,9,15-trioxatetracyclo[11.2.1.0%¢.0%!Jhexadec-13(16)-ene-4, 14-dione; - 12-(dimethylamino)-3,8-dimethyl-4,14-dioxo- 5,9,15-trioxatetracyclo[11.2.1.0%¢.0*'"hexadec-1 3(16)-en-11-yl benzoate; - 12-(dimethylamino)-3,8-dimethyl-4,14-diox0-5,9,15- trioxatetracyclo[11.2.1.0%°.0*!Jhexadec-13(16)-en-1 1-yl cyclohexanecarboxylate; - 12-(dimethylamino)-3,8-dimethyl-4,14-diox0-5,9,15- trioxatetracyclo[11.2.1 07°.0*")hexadec-1 3(16)-en-11-yl 4-fluorobenzoate;
_ LL - 12-(dimethylamino)-3,8-dimethyl-4,14-dioxo-5,9,15- trioxatetracyclo[11.2.1 .026.0%'%hexadec- 13(16)-en-11-yl 2-thiophenecarboxylate; - 12-(dimethylamino)-3,8-dimethyl-4,14-dioxo-5,9,15- trioxatetracyclo[11.2.1.0%%.0%!%Jhexadec-13(16)-en-11-yl 3,3-dimethylbutanoate; -12-(dimethylamino)-3,8-dimethyl-4,14-dioxo-5,9,15-trioxatetracyclo[11.2.1 026.0%] hexadec-13(16)-en-11-yl 1-benzothiophene-2-carboxylate; - 8-(dimethylamino)-3,10a -dimethyl-2,6-dioxodecahydro-4,7-methenofuro[3,2- c]oxireno[fJoxacycloundecin-9-yl 4-tert-butylphenylcarbamate; - 8-(dimethylamino)-3,10a -dimethyl-2,6-dioxodecahydro-4,7-methenofuro[3,2- c]oxireno[f]oxacycloundecin-9-yl 2-ethoxyphenylcarbamate; ® as well as their salts.
As regards the salts of compounds of general formula (I), the maleates, fumarates, methanesulphonates and hydrochlorides of compounds of general formula (I) are preferred, and in particular those described in the examples, namely: - 11-hydroxy-3,8-dimethyl-4,14-dioxo-5,9,15-trioxatetracyclo[11.2.1.0%¢.0%!*Jhexadec- 13(16)-ene-12-yl(dimethyl)ammonium maleate; - 11-hydroxy-3,8-dimethyl-4,14-dioxo-5,9,1 5-trioxatetracyclo[11.2.1 .0%¢.0%"%Thexadec- 13(16)-ene-12-yl(dimethyl)ammonium fumarate; - 11-hydroxy-3,8-dimethyl-4,14-dioxo-5,9,1 5-trioxatetracyclo[ 11.2.1 076.0% hexadec- 13(16)-ene-12-yl(dimethyl)ammonium methanesulphonate; - 11-{[tert-butyl(dimethyl)silyl]oxy}-12-(dimethylamino)-3,8-dimethyl-5,9,15- [ trioxatetracyclo[11.2.1 .0%6.0%'% hexadec-1 3(16)-ene-4,14-dione hydrochloride; and - 12~(dimethylamino)-3,8-dimethyl-4,14-dioxo-5,9,15-trioxatetracyclo[ 11.2.1.0%6.0%1%) hexadec-13(16)-en-11-yl 2-thiophenecarboxylate hvdrochloride.
A subject of the invention is also the compounds of general formula (I)'
_ ”
M os
L' = ~
S “0 0 o 0
R, @’ ® corresponding to general sub-formulae (I)’; and (I)’;
R
3
Oo Me 0 0 Me
Re. > $x 2 0 3 0 B & “0 0 0) o
Oo Oo
R, R
MH" (I: in which ® Rj represents a hydrogen atom or an SR4 or NR4R; radical;
Rj represents SR¢ or NRgR7.
Rs represents OH, O(CO)R 4, O(CO)OR 4, OF OSiR sR 16R 7.
R4, and Rg represent, independently, an alkyl radical, a cycloalkyl, cycloalkylalkyl, hydroxyalkyl radical or also one of the aryl or aralkyl radicals optionally substituted on their aryl group by one or more radicals chosen from the alkyl, hydroxy or alkoxy radicals,
Rs and R; represent, independently, a hydrogen atom, an alkyl radical, a cycloalkyl, cycloalkylalkyl, hydroxyalkyl radical or also one of the aryl or aralkyl radicals
® ® a optionally substituted on their aryl group by one or more radicals chosen from the alkyl, hydroxy or alkoxy radicals,
R4 and Rs being able to form together with the nitrogen atom which carries them a heterocycle with 5 to 7 members, the additional members being chosen from the -CRgRe-, -NR|¢-, -O- and -S- radicals, it being understood however that there can only be one member chosen from -O- or -S- in said heterocycle, and Rs and Ry being able to form together with the nitrogen atom which carries them a heterocycle with 5 to 7 members, the additional members being chosen from the -CR}1Ri2-, -NR3-, -O- and -S- radicals, it being understood however that there can only be one member chosen from -O- or -S- in said heterocycle,
Rs, Rio, R11 and Rj; represent, independently each time they are involved, a hydrogen atom or an alkyl, alkoxycarbonyl or aralkyl radical, ® Ry and R; representing, independently each time they are involved, a hydrogen atom or each of Ry and R;, being able to form respectively with Rg and R;; an -O-(CH;),-O- radical attached on either side to the carbon atom which carries them, such a radical only being present however once at most per NR4Rs or NR¢R radical, represent, independently each time they are involved, a hydrogen atom or an alkyl radical;
Ri4 represents an alkyl or cycloalkyl radical or one of the aryl, heteroaryl, aralkyl or heteroaralkyl radicals optionally substituted on their aryl or heteroaryl group by one or more radicals chosen from a halogen atom and the alkyl, haloalkyl, nitro, hydroxy or alkoxy radicals;
Ris, Ris and Ry; represent, independently, an alkyl radical or a phenyl radical; o it being understood however that when the compounds correspond to general sub- formula (I)’2, then R; does not represent a hydrogen atom; or the salts of the latter.
A subject of the invention is also the compounds of general formula (I)*’
® Ls. 0 Me
L' : . > 0
Oo 0
Oo
R, a> @® corresponding to the general sub-formulae (I)*’y and (I)’’;
R
3
O Ne ow o Me
R... Pe TX 2 . \ 0 HR 0 9) EEN CY
Oo 0
R, R, {M’" I)’ o in which R, represents a hydrogen atom or an SR4 or NR4R radical;
R, represents SR¢ or NR¢R7.
Rj represents OH, O(CO)R 14, O(CO)OR 4, or OSiR sR sR 7.
R4, Rs, Rs and Ry represent, independently, a hydrogen atom, an alkyl radical, a cycloalkyl, cycloalkylalkyl, hydroxyalkyl radical or also one of the aryl or aralkyl radicals optionally substituted on their aryl group by one or more radicals chosen from the alkyl, hydroxy or alkoxy radicals,
R; and Rs can form together with the nitrogen atom which carries them a heterocycle with 5 to 7 members, the additional members being chosen from the -CRsRo-, -NR-,
® ® -16- -O- and -S- radicals, it being understood however that only one member chosen from -O- or -S- can be found in said heterocycle, and R¢ and R; can form together with the nitrogen atom which carries them a heterocycle with 5 to 7 members, the additional members being chosen from the -CRyRj2-, -NRj3-, -O- and -S- radicals, it being understood however that only one member chosen from -O- or -S- can be found in said heterocycle,
Rs, Rio, Ri1 and Ry3 represent, independently each time they are involved, a hydrogen atom or an alkyl, alkoxycarbonyl or aralkyl radical,
Ry and R; representing, independently each time they are involved, a hydrogen atom or each of Ry and Rj; can form with Rg and Rj; respectively an -O-(CH;),-O- radical attached on either side to the carbon atom which carries it, such radical however only being present at most once per NR4Rs or NRgR7 radical, represent, independently each ® time they are involved, a hydrogen atom or an alkyl radical;
Ri4, Ris, Ris and Ry7 represent, independently, a hydrogen atom, an alkyl radical or one of the aryl or aralkyl radicals optionally substituted on their aryl group by one or more radicals chosen from the alkyl, hydroxy or alkoxy radicals; it being understood however that when the compounds correspond to the general sub- formula (I)’’2, then R; does not represent a hydrogen atom; or the salts of the latter.
The compounds of the present invention can inhibit abnormal cell proliferation in a patient, for example a mammal such as man, by administration to this patient of a therapeutically effective quantity of a compound of general formula (I), (I)' or (I)'"" or ® of a pharmaceutically acceptable salt of such a compound.
The compounds of general formula (I), (I)' or (I)" have an anti-tumoral activity. They can be used for the treatment of tumors in a patient by administration to said patient of a therapeutically effective quantity of a compound of general formula (I), (I)! or (I)" or of a pharmaceutically acceptable salt of such a compound. Examples of tumors or cancers include cancers of the oesophagus, stomach, intestines, rectum, buccal cavity, pharynx, larynx, lung, colon, breast, cervix uteri, corpus endometrium, ovaries, prostate, testicles, bladder, kidneys, liver, pancreas, bone, connective tissues, skin, for example melanomas, eyes, brain and central nervous system, as well as cancer of the thyroid, leukemia, Hodgkin’s disease, lymphomas other than those of Hodgkin’s disease, multiple myelomas and others.
_
They can also be used for the treatment of parasitic infections by inhibition of the hemoflagellates (for example in trypanosomia or leishmania infections) or by inhibition of the plasmodia (such as for example in malaria), but also the treatment of viral infections and diseases.
These properties make the compounds of the invention suitable for pharmaceutical use.
A subject of the invention is therefore also, as medicaments, the compounds of general formula (I), (I)! or (I)! described previously or their pharmaceutically acceptable salts.
It also relates to pharmaceutical compositions containing these compounds or their pharmaceutically acceptable salts. A further subject of the invention is the use of these compounds or their pharmaceutically acceptable salts in order to produce medicaments intended to inhibit DNA polymerases, and in particular to treat diseases due to [ abnormal cell proliferation (in particular cancer or atherosclerosis, benign hyperplasia of the prostate and fibroses), as well as viral diseases and parasitic diseases, in particular those caused by protozoans (for example malaria) or protists (for example diseases caused by amoebae). Finally, the invention relates to the use of the compounds of general formula (I), (I)' or (I)"" described previously or their pharmaceutically acceptable salts for preparing a medicament intended to treat diseases of bacterial origin.
By pharmaceutically acceptable salt is meant in particular addition salts of inorganic acids such as hydrochloride, hydrobromide, hydroiodide, sulphate, phosphate, diphosphate and nitrate or organic acids such as acetate, maleate, fumarate, tartrate, succinate, citrate, lactate, methanesulphonate, p-toluenesulphonate, pamoate and stearate. The salts formed from bases such as sodium or potassium hydroxide also fall within the scope of the present invention, when they can be used. For other examples of @® 25 pharmaceutically acceptable salts, reference can be made to "Salt selection for basic drugs”, Int. J. Pharm. (1986), 33, 201-217.
The pharmaceutical compositions containing a compound of the invention can be in solid form such as, for example, powders, pills, granules, tablets, liposomes, gelatin capsules or suppositories. The pills, tablets or gelatin capsules can be coated with a substance capable of protecting the composition from the action of the gastric acid or the enzymes in the subject’s stomach for a sufficient period of time to allow this composition to pass undigested into the subject’s small intestine. The compound can also be administered locally, for example at the precise location of a tumor. The compound can also be administered according to a sustained release process (for example using a sustained release composition or a perfusion pump). Appropriate solid supports can be, for example, calcium phosphate, magnesium stearate, magnesium
® . carbonate, talc, sugars, lactose, dextrin, starch, gelatin, cellulose, methyl cellulose, sodium carboxymethyl cellulose, polyvinylpyrrolidine and wax.
The pharmaceutical compositions containing a compound of the invention can also be presented in liquid form such as, for example, solutions, emulsions, suspensions or a sustained release formulation. Appropriate liquid supports can be, for example, water, organic solvents such as glycerol or glycols such as polyethylene glycol, as well as their mixtures, in varying proportions, in water.
The administration of a medicament according to the invention can be carried out by topical, oral, parenteral route, by intramuscular injection, etc. ® 10 The dose of a compound according to the present invention, to be provided for the treatment of the diseases or disorders indicated above, varies according to the method of administration, the age and the body weight of the subject to be treated as well as the latter’s state, and the final decision is made by the attending doctor or veterinary surgeon. Such a quantity determined by the attending doctor or veterinary surgeon is here referred to as "therapeutically effective quantity”.
The same preferences as those indicated previously for the compounds of general formula (I) are applicable mutatis mutandis to the compounds of general formula (I)! or (D", to the medicaments of general formula (I), (I)' or (I)", to the pharmaceutical compositions containing a compound of general formula (I), (I)! or (I)"' and to the uses of a compound of general formula (I), (I)* or (I)'" for preparing medicaments.
According to the invention, the compounds of general formula (I), (I)' or (I)'"" can be ® prepared by the processes described hereafter.
Preparation of compounds of general formula (I). (I)' or (I)"' and their salts
Preparation of compounds of general sub-formula (I);:
CASE Ll: Ri =H:
The preparation of this type of compound is summarized in Diagram 1 hereafter. The dihydromikanolide by adding a nucleophile such as a primary or secondary amine
HNRgR7, or also a thiol R¢SH in the presence of a base, in an inert solvent such as tetrahydrofuran or acetone, at a temperature preferably comprised between 0 °C and 50 °C, and more preferentially at ambient temperature.
® ® -19-
In the case where Rj is not OH, the intermediate obtained is treated with one of the reagents of general formula R4(CO)-Hal (or an equivalent reagent such as for example the anhydride (R;4(CO)),0), R;sO(CO)-Hal, Hal-Si RsR|6R;7; (Hal representing a halogen atom) or Rig-NCO in order to obtain the desired final compound. Generally, this reaction is carried out in an aprotic solvent such as dichloromethane, trichloroethane, acetonitrile, tetrahydrofuran or toluene, at a temperature preferably comprised between 0 °C and 110 °C and optionally in the presence of a base such as triethylamine or 4-dimethylaminopyridine. These types of reaction are well known to a person skilled in the art (who can in particular usefully consult the following reference publication: Greene et al., "Protective groups in Organic Synthesis", 2nd edition,
Wiley, New-York, 1991) owing to their frequent use for protecting an alcohol or amine function. For example, as regards the silylation reaction, this is generally carried out by ® treatment of an alcoholic compound with a silyl chloride in the presence of a base, in an aprotic solvent at a temperature comprised between 0 °C and 50 °C.
R o M HNR(R, 2g Me
A orR SH, base R.. : XN pr ., optionally followed by — y \ “O R,,CO-Hal, R, O(CO)-Hal, \ "O
Oo o SiR, sR, R,-Hal or O o 0 R,+~-NCO o ® Diagram 1
An additional method for obtaining compounds with R3 = OCOR 4 consists of treating the intermediate alcohol with the acid R;3-COOH in the presence of a base, such as for example dimethylaminopyridine, and a coupling agent, such as for example 1-(3-dimethylaminopropyl)-3-ethylcarbodiimide hydrochloride (EDC.HCI).
CASE 2: Ri =RozH:
The compounds of formula (I); in which Ry = R;# H and Rj; represents a hydroxyl group can be prepared from mikanolide by adding a nucleophilic such as a primary or secondary amine HNR4Rs, or also a thiol R4SH in the presence of a base, in an inert solvent such as tetrahydrofuran or acetone, at a temperature preferably comprised between 0 °C and 50 °C, and more preferentially at ambient temperature.
® A.
In the case where Rj is not OH, a second reaction is carried out using a compound of general formula Rj 4(CO)-Hal (or an equivalent reagent such as for example (R14(C0O))0), Ris0(CO)-Hal or Hal-SiRjsRj¢R;; anhydride (Hal representing a halogen atom) or R;3-NCO in order to obtain the desired final compound. This reaction can be carried out in a manner analogous to that disclosed in CASE 1. 0) Me HNR,R; RS Me
O S or R,SH, base O N - 1 — } optionally followed by — } \ “0 R,,CO-Hal, R,,0(CO)-Hal, \ “0 o) 3 SiR, RR, ,-Hal 0) S 0 or R,-NCO O ® 7 Co °
R,
Diagram 2
An additional method for obtaining compounds with R; = OCOR 4 consists of treating the intermediate alcohol with the acid Ri4-COOH in the presence of a base, such as for example dimethylaminopyridine, and of a coupling agent, such as for example 1-(3-dimethylaminopropyl)-3-ethylcarbodiimide hydrochloride (EDC.HC])).
CASE 3: Ri = Hand Ry # Ro.
In this case, the compound of general formula (I); is subjected to the same reactions as
C in CASE 1 in order to produce the desired final compound in which R; # Rs. 9) Me HNR,R; R, Me o S or R,SH, base 0 S = R.... = _—— 2 — ! optionally followed by — } \ “0 R,,CO-Hal, R, ,COO-Hal \ “0 0) & SiR, RR, ,-Hal or 0) &
O RISNCO 0
Oo Oo
R, R ;
OF
Diagram 3 n
Preparation of compounds of general sub-formula (I):
The compounds of sub-formula (I); can be prepared, Diagram 4, from mikanolide by adding a nucleophile such as a primary or secondary amine HNR4R7, or also a thiol
R¢SH in the presence of a base, in an inert solvent such as tetrahydrofuran or acetone, at a temperature preferably comprised between 0 °C and 50 °C, and more preferentially at ambient temperature.
Me Me
Os. 0: HNR(R, OS. Ou: > or RSH, base = —_—_— h ie) A “0 ® Te Te / “o 0
R
1 a),
Diagram 4
Salts of compounds of general formula (I):
Certain compounds of the invention can be prepared in the form of pharmaceutically acceptable salts according to the usual methods. As regards these salts, a person skilled in the art can usefully consult the article by Gould et al., "Salt selection for basic drugs", Int. J. Pharm. (1986), 33, 201-217.
Unless otherwise specified, all the technical and scientific terms used here have the same meaning as that usually understood by an ordinary specialist in the field to which this invention belongs. Similarly, all the publications, patent applications, all the patents and all other references mentioned here are incorporated by way of reference.
The following examples are presented in order to illustrate the above procedures and should in no event be considered as a limit to the scope of the invention.
® Lo
The nomenclature used for the examples in principle conforms with the IUPAC standards. It was determined using the ACD/Name" software (version 4.53) for examples 1 to 36 and using the ACD/Name® software (version 5.00) for examples 37 to 52
The numbering indicated in the figure below is used for examples 1 to 36 as regards the positions of the substituents -CH>-R;, Ry and R; on the polycycles of general sub-
Jormulae (I); and (I) »: 1 0 Me Io) 0 Me
A 0 \ 0
Oo o 0) o 3 O 12 (0)
Example 1: 12-diisopropylaminomethyl-7-methyl-3.6,10,15-tetraoxapentacyclo [12.2.1.0%%.0°7.0>"*|heptadec-1(17)-ene-11,16-dione:
Diisopropylamine (500 umol; 70 ul) is added to a solution of mikanolide (100 pmol; 29 mg) in acetone (l ml). The reaction mass is stirred for 30 minutes at ambient temperature then the solvent is eliminated by evaporation under reduced pressure. The residue is taken up in ether, filtered and dried under vacuum. 10 mg of product is obtained in the form of a white powder.
NMR-'H (DMSO): 0.90-1.30 (m, 15H); 1.85 (m, 2H); 2.15 (i, 2H); ® 3.15-3.50 (m, 4H); 3.95 (s, 1H); 4.75 (m, 1H); 5.50 (s, 1H); 6.00 (s, 1H); 6.25 (s, 1H); 7.60 (s, 1H).
Example 2: 12-dimethylamino-3-dimethylaminomethyl-11-hydroxy-8-methyl- 5,9,15-trioxatetracyclo[11.2.1.0>%.0*'’|hexadec-13(16)-ene-4,14-dione:
A solution of dimethylamine (160 pmol; 80 ul; 2M in THF) is added to a solution of mikanolide (30 umol; 9 mg) in acetone (0.3 ml). The reaction mass is stirred for 30 minutes at ambient temperature then concentrated under reduced pressure. The residue is taken up in ether, filtered and dried under vacuum. 6 mg of expected compound is obtained in the form of a white powder.
® ® -23-
NMR-'H (DMSO): 1.11 (s, 3H); 1.94-1.97 (m. 2H); 2.20 (s, 6H); 2.47 (s, 6H); 2.67 (m, 2H); 2.85 (t, 1H); 3.07 (d, 1H); 3.15 (m, 1H); 3.52 (d, 1H); 3.63 (m, 1H); 4.62 (m, IH); 5.36 (s, 1H); 5.47 (s, 1H); 8.00 (s, 1H).
NMR-"C (DMSO): 20.68; 42.85; 43.37; 44.71; 45.92; 49.95; 57.84; 58.24; 61.61; 62.97; 67.94; 77.09; 80.67; 131.46; 151.01; 172.03; 174.98.
Example 3: 12-benzyl(methyl)amino-3-benzyl(methyl)aminomethyl-11-hydroxy-8- methyl-5,9,15-trioxatetracyclo[11.2.1.0%°.0*'"|hexadec-13(16)-ene-4,14-dione:
This compound is obtained by a procedure similar to that described for the synthesis of the compound of Example 2. The expected product is obtained in the form of a white powder. ® NMR-'H (DMSO): 1.12 (s, 3H); 1.96 (m, 2H); 2.10 (m, 1H); 2.15 (s, 3H); 2.47 (m, 2H); 2.83 (d, 2H); 2.89 (d, 1H); 3.22 (d, 1H), 3.26 (m, 1H); 3.58 (dd, 2H); 3.69 (m, 1H); 3.89 (d, 1H); 3.93 (s, 2H); 4.73 (m, 1H); 5.47 (d, 1H); 5.52 (s, 1H); 7.23-7.40 (m, 10H); 8.10 (s, 1H).
NMR-"C (DMSO): 20.65; 39.08; 40.54; 42.09; 43.09; 43.52; 50.18; 56.57; 57.85; 60.17; 61.14; 62.21; 62.33; 68.37; 77.22; 81.01; 126.07; 128.30; 131.48; 138.88; 139.67; 150.35; 172.16; 175.18.
Example 4: 11-hydroxy-8-methyl-12-morpholino-3-morpholinomethyl- 5,9,15-trioxatetracyclo[11.2.1.0%%.0%jhex adec-13(16)-ene-4,14-dione:
This compound is obtained by a procedure similar to that described for the synthesis of the compound of Example 2. The expected product is obtained in the form of a white powder. ® NMR-'H (DMSO): 1.13 (s, 3H); 1.85-2.10 (m, 2H); 2.36 (m, 2H); 2.40 (m, 2H); 2.74 (m, 4H); 2.88 (t, 1H); 2.95 (m, 2H); 3.10 (d, 1H); 3.24 (m, 1H); 3.50-3.70 (m, 10H); 4.64 (m, 1H); 5.49 (s, 1H); 5.50 (d, 1H); 8.01 (s, 1H).
Example 5: 12-dimethylamino-11-hydroxy-3,8-dimethyl- 5,9,15-trioxatetracyclo[1 1.2.1.0%5.0*°|hexadec-13(16)-ene-4,14-dione:
A solution of dimethylamine (500 pmol, 250 pl, 2M in THF) is added to a solution of dihydromikanolide (100 pmol, 29 mg) in acetone (1 ml). The reaction mass is stirred for 2 hours at ambient temperature then the solvent is eliminated by evaporation under reduced pressure. The residue is taken up in ether, filtered and dried under vacuum. 25 mg of product is obtained in the form of a white powder.
® ® -24-
NMR-'H (DMSO): 1.10 (s, 3H); 1.25 (d. 3H). 1.90 (dd, 1H); 1.99 (t, 1H); 2.49 (s, 6H); 2.58 (t, 1H); 2.94 (m, 1H); 3.06 (d, 1H); 3.51 (m, 1H); 3.63 (m, 1H); 4.62 (m, 1H); 5.34 (s, 1H); 5.37 (d, 1H); 8.00 (s, 1H).
Example 6: 11-hydroxy-3,8-dimethyl-4,14-dioxe-5,9,15-trioxatetracyclo [11.2.1.0%%.0*'°)hexadec-13(16)-ene-12-yl(dimethyl)ammonium maleate:
A solution of maleic acid (0.1 mmol; 11.6 mg) in acetone (0.5 ml) is added to a solution of the compound of Example 5 (0.1 mmol; 34 mg) in acetone (0.5 ml). The precipitate is filtered, washed with acetone and dried under reduced pressure. 24 mg of the expected product is obtained in the form of a white powder. Melting point: 178.5 °C.
NMR-'H (DMSO): 1.09 (s, 3H); 1.28 (d, 3H); 1.94 (dd, 1H); 2.05 (m, 1H); ® 2.63 (t, 1H); 2.70-3.70 (m, 9H); 3.79 (t, 1H); 4.38 (s, 1H); 4.68 (m, 1H); 5.45 (s, 1H); 6.07 (s, 2H); 8.31 (s, 1H).
Example 7: 11-hydroxy-3,8-dimethyl-4,14-dioxo-5,9,15-trioxatetracyclo 1 1.2.1.0%%,0%'*| hexadec-13(16)-ene-12-yl(dimethyl)ammonium fumarate:
A solution of fumaric acid (0.1 mmol; 11.6 mg) in acetone (3 ml) is added to a solution of the compound of Example 5 (0.1 mmol; 34 mg) in acetone (0.5 ml). The precipitate 1s filtered, washed with acetone and dried under reduced pressure. 15 mg of the expected product is obtained in the form of a white powder. Melting point: 159 °C.
NMR-'H (DMSO): 1.11 (s, 3H); 1.25 (d, 3H); 1.92 (dd, 1H); 2.02 (m, 1H); 2.58 (t, 1H); 2.80-4.00 (m, 11H); 4.64 (m, 1H); 5.34 (s, 1H); 6.61 (s, 2H); 8.01 (s, 1H).
Example 8: 11-hydroxy-3,8-dimethyl-4,14-dioxo-5,9,15-trioxatetracyclo 1 1.2.1.0%%.0*'" hexadec-13(1 6)-ene-12-yl(dimethyl)ammonium ® methanesulphonate:
A solution of methanesulphonic acid (0.1 mmol; 1 ml; 0.1V in acetone) is added to a solution of the compound of Example 5 (0.1 mmol; 34 mg) in acetone (2 ml). The precipitate is filtered, washed with acetone and dried under reduced pressure. 24 mg of the expected product is obtained in the form of a white powder. Melting point: 220 °C.
NMR-'H (DMSO): 1.09 (s, 3H); 1.29 (d, 3H); 1.97 (dd, 1H); 2.07 (m, 1H), 2.30 (s, 3H); 2.65 (t, 1H); 2.80-3.15 (m, 7H); 3.28 (d, lH); 3.85 (t, 1H); 4.66-4.72 (m, 2H); 5.49 (s, 1H); 6.94 (s, 1H); 8.44 (s, 1H); 10.04 (s, 1H).
® .
Example 9: 11-hydroxy-3,8-dimethyl-12-(4-methylpiperidino)- 5,9,15-trioxatetracyclo] 11.2.1.0*%.0*'°|hexadec-13(16)-ene-4,14-dione:
This compound is obtained by a procedure similar to that described for the synthesis of the compound of Example 5. The expected product is obtained in the form of a white powder. Melting point: 210 °C.
NMR-'H (DMSO): 0.80-3.50 (m, 23H); 3.60-3.75 (m, 2H); 4.62 (m, 1H); 5.32 (s, 2H); 8.01 (s, 1H).
Example 10: 11-hydroxy-3,8-dimethyl-12-pyrrolidino- 5,9,15-trioxatetracyclo[11.2.1.0%°.0*'°|hexadec-13(16)-ene-4,14-dione: ® 10 This compound is obtained by a procedure similar to that described for the synthesis of the compound of Example 5. The expected product is obtained in the form of a white powder.
NMR-'H (DMSO): 1.12 (s, 3H); 1.25 (d, 3H); 1.69 (m, 4H); 1.91 (dd, 1H); 2.00 (m, 1H); 2.60 (t, 1H); 2.80 (m, 4H); 2.95 (m, 1H); 3.02 (d, 1H); 3.45 (s, 1H); 3.63 (mm, 1H); 4.61 (m, 1H); 5.34 (s, 1H); 5.42 (d, 1H); 7.97 (s, 1H).
Example 11: ethyl 1-[11-hydroxy-3,8-dimethyl-4,14-diox0-5,9,15-trioxatetracyclo [11.2.1.0>%.0*"|hexadec-13(16)-ene-12-yl]-4-piperidinecarboxylate:
This compound is obtained by a procedure similar to that described for the synthesis of the compound of Example 5. The expected product is obtained in the form of a white powder.
NMR-'H (DMSO): 1.00-4.00 (m, 25H); 4.04 (q, 2H); 4.64 (m, 1H); 5.35 (s, 1H); 5.48 ® (d, 1H); 8.07 (s,1H).
Example 12: 12-(4-benzylpiperidino)-11-hydroxy-3,8-dimethyl- 5,9,15-trioxatetracyclo[11.2.1.0%¢.0*'’|hexadec-13(16)-ene-4,14-dione:
This compound is obtained by a procedure similar to that described for the synthesis of the compound of Example 5. The expected product is obtained in the form of a white powder.
NMR-'H (DMSO): 1.00-1.80 (m, 12H); 1.85-2.10 (m, 2H); 2.35-4.00 (m, 6H); 4.63 (m, 1H); 5.33 (m, 2H); 7.00-7.20 (m, 5H); 8.03 (s, 1H).
® "
Example 13: 11-hydroxy-3,8-dimethyl-12-piperidino- 5,9,15-trioxatetracyclo[11.2.1.0>°.0%'*|hexadec-13(16)-ene-4,14-dione:
This compound is obtained by a procedure similar to that described for the synthesis of the compound of Example 5. The expected product is obtained in the form of a white powder.
NMR-'H (DMSO): 1.11 (s, 3H); 1.26 (d, 3H); 1.35-1.70 (m, 6H); 1.85-2.14 (m, 2H); 2.57-3.18 (m, 7H); 3.50-3.75 (m, 2H); 4.64 (m, 1H); 5.34 (m, 2H); 8.04 (s, 1H).
Example 14: 12-(1,4-dioxa-8-azaspiro[4.5)dec-8-yl)-11-hydroxy-3,8-dimethyl- 5,9,15-trioxatetracyclo[11.2.1.0*%.0%'*|hexadec-13(16)-ene-4,14-dione:
This compound is obtained by a procedure similar to that described for the synthesis of ® the compound of Example 5. The expected product is obtained in the form of a white powder.
NMR-'H (DMSO): 1.11 (s, 3H); 1.26 (d, 3H); 1.40-1.80 (m, 6H); 1.85-2.05 (m, 2H); 2.58-4.00 (m, 17H); 4.67 (m, 1H); 5.37 (s, 1H); 5.44 (d, 1H); 8.08 (s, 1H).
Example 15: 11-hydroxy-3,8-dimethyl-12-morpholino- 5,9,15-trioxatetracyclo[1 1.2.1.0%%.0%'")hexadec-13(16)-ene-4,14-dione:
This compound is obtained by a procedure similar to that described for the synthesis of the compound of Example 5. The expected product is obtained in the form of a white powder.
NMR-'H (DMSO): 1.10 (s, 3H); 1.25 (d, 3H); 1.89 (dd, 1H); 2.01 (m, 1H); 2.61 (t, 1H); 2.75 (m, 2H); 3.95 (m, 3H); 3.08 (d, 1H); 3.55-3.75 (m, 5H); ® 4.63 (1H); 5.33 (s, 1H); 5.54 (d, 1H); 8.04 (s, 1H).
Example 16: 11-(fer-butyldimethylsiloxy)-12-dimethylamino-3,8-dimethyl-5,9,15- trioxatetracyclo[11.2.1.0*%.0*'"|hexadec-13(16)-ene-4,14-dione: Terbutyldimethylsilyl chloride (80 umol, 12mg) is added to a solution of the compound of Example 5 (80 pmol; 27 mg) and imidazole (160 pmol; 11 mg) in DMF (0.5 ml). The solution obtained is stirred for 20 hours then the reaction mass is poured into water. The aqueous phase is extracted twice with ethyl acetate, the organic phase is washed with water then with a solution of sodium chloride. The organic phase is dried over magnesium sulphate, filtered then evaporated. The residue is eluted on silica with a mixture of isopropyl acetate and dichloromethane (20/80). 20 mg of product is obtained in the form of a white powder.
® ® -27-
NMR-'H (DMSO): 0.04 (s, 3H); 0.07 (s, 3H); 0.89 (s, 9H); 1.14 (s, 3H); 1.25 (d, 3H); 1.90 (dd, 1H); 1.99 (dd, 1H); 2.48 (s, 6H); 2.63 (1, 1H); 2.93-2.98 (m, 1H); 3.12 (d, 1H); 3.43 (m, 1H); 3.80 (m, 1H); 4.61 (m, 1H); 5.36 (s, 1H); 8.03 (s, 1H).
Example 17: 3,8-dimethyl-12-(4-methylpiperidino)-4,14-dioxo- 5,9,15-trioxatetracyclof{11.2.1.0%%.0%'%|hexadec-13(16)-en-11-yl acetate:
Acetic anhydride (150 pmol; 15 pl) is added to a solution of the compound of Example 9 (100 pmol; 40 mg) in pyridine (0.5 ml). The solution obtained is stirred for 20 hours then the reaction mass is poured into water. The aqueous phase is extracted twice with ethyl acetate and the organic phase obtained is washed with water then with a solution of sodium chloride. The organic phase is dried over magnesium sulphate, filtered then ® evaporated. The residue is eluted on silica with a mixture of isopropyl acetate and dichloromethane (20/80). 16 mg of product is obtained in the form of a white powder.
NMR-'H (DMSO): 0.90 (d, 3H); 1.11 (s, 3H); 1.26 (d, 3H); 1.35 (m, IH); 1.60 (m, 2H), 1.94 (dd, 1H); 2.03 (d, 1H); 2.09 (s, 3H); 2.43 (t, 1H); 2.60 (t, 1H); 2.98 (d, 1H); 2.94-3.05 (m, 2H); 3.36-3.45 (m, 4H); 4.07 (d, 1H); 4.64 (dd, 1H); 4.70 (m, 1H); 5.38 (s, 1H); 8.12 (s, 1H).
Example 18: 3,8-dimethyl-12-(4-methylpiperidino)-4,14-dioxo- 11-phenylcarbonyloxy-5,9,15-trioxatetracyclo[11.2.1.0*%.0%"’|hexadec-13(16)-ene:
Benzoyl chloride (400 pmol; 46 pl) is added to a solution of the compound of Example 9 (100 pmol; 40 mg) in pyridine (0.5 ml). The reaction mass is stirred for 2 hours then treated in the same manner as for the preparation of the compound of Example 17. mg of product is obtained in the form of a white powder. Melting point: 234 °C. ® NMR-'H (DMSO): 0.73 (d, 3H); 1.18 (s, 3H); 1.25 (m, 1H); 1.27 (d, 3H), 1.45-1.60 (m, 2H); 2.00 (dd, 1H); 2.10 (m, 1H); 2.65 (t, 1H); 2.92-3.15 (m, 3H); 25 3.45 (m, 2H); 3.54 (d, 1H); 4.18 (d, 1H); 4.36 (t, tH); 4.74 (m, 1H); 4.95 (t, 1H); 5.41 (s, IH); 7.58 (t, 2H); 7.70 (t, 1H); 8.01 (d, 2H); 8.19 (s, 1H).
Example 19: ethyl 3,8-dimethyl-12-(4-methylpiperidino)-4,14-dioxo- 5,9,15-trioxatetracyclo[11.2. 1.0%°.0%'% hexadec-13(1 6)-en-11-yl carbonate:
Ethyl chloroformate (300 umol; 28 ul) is added to a solution of the compound of
Example 9 (100 pmol; 40 mg) in pyridine (0.5 ml). The reaction mass is stirred for 2 hours then treated in the same manner as for the preparation of the compound of
Example 17. 20 mg of product is obtained in the form of a white powder.
® ® -28-
NMR-'H (DMSO): 0.88 (d, 3H); 1.10-1.40 (m, 12H); 1.59 (m, 2H); 2.90-2.10 (m, 2H); 2.35-2.50 (m, 2H); 2.58 (t, 1H); 2.80 (d, 1H); 2.95-3.07 (m, 2H); 3.40 (d, 1H); 4.11- 4.25 (m, 3H); 4.43 (dd, 1H); 4.70 (m, 1H); 5.39 (s, 1H); 8.13 (s, 1H).
Example 20: 11-hydroxy-12-isobutylsulphanyl-3-isobutylsulphanylmethyl-8- methyl-5,9,15-trioxatetracyclo{11.2.1.0>%.0*!|hexadec-13(16)-ene-4,14-dione: 2-methyl-1-propanethiol (500 umol; 54 pl) is added to a solution of mikanolide (100 pmol; 30 mg) and dimethylaminopyridine (10 umol; 1.2 mg) in acetone (1 ml).
The reaction mass is stirred for two hours at ambient temperature then the solvent is evaporated off under reduced pressure. The residue is taken up in ether, the precipitate is filtered, washed with ether and dried under vacuum. 35 mg of product is obtained in ® the form of a white powder.
NMR-'H (DMSO): 0.96 (m, 12H); 1.15 (s, 3H); 1.77 (m, 2H); 1.93 (d, 2H); 2.50 (m, 4H); 2.80-2.98 (m, 4H); 3.39 (m, 1H); 3.76 (m, 1H); 4.07 (d, 1H); 4.62 (q, 1H); 5.52 (s, 1H); 5.62 (s, 1H); 8.06 (s, 1H).
Example 21: 11-hydroxy-12-isobutylsulphanyl-3,8-dimethyl- 5,9,15-trioxatetracyclo[11.2.1.0*%.0%'"|hexadec-13(16)-ene-4,14-dione: 2-methyl-1-propanethiol (500 pmol; 54 ul) is added to a solution of dihydromikanolide (100 pmol; 30 mg) and dimethylaminopyridine (10 pmol; 1.2 mg) in acetone (1 ml).
The reaction mass is stirred for two hours at ambient temperature then the solvent is evaporated off under reduced pressure. The residue is taken up in ether then the precipitate formed is filtered, washed with ether and dried under vacuum. 25 mg of product is obtained in the form of a white powder. ® NMR-'H (DMSO): 0.96 (t, 6H); 1.13 (s, 3H); 1.25 (d, 3H); 1.78 (m, 1H); 1.89 (dd, 1H); 2.00 (t, 1H); 2.48 (m, 2H); 2.62 (t, 1H); 2.82 (d, 1H), 2.98 (m, 1H); 3.78 (m, 1H); 4.07 (d, 1H); 4.57 (m, 1H); 5.40 (s, 1H); 5.61 (d, 1H); 8.06 (s, 1H).
Example 22: 12-(dimethylamino)-3,8-dimethyl-4,14-dioxo- 5,9,15-trioxatetracyclo[11.2.1.0*%.0* |hexadec-13(16)-en-11-yl benzoate:
This compound is obtained by a procedure similar to that described for the synthesis of the compound of Example 18. The expected product is obtained in the form of a white powder.
NMR-'H (DMSO):1.21 (s, 3H); 1.28 (d, 3H); 1.98 (dd, 1H); 2.08 (t, 1H); 2.48 (s, 6H); 2.66 (t, 1H); 3.01 (m, 1H); 3.51 (d, 1H); 4.04 (d, 1H); 4.71 (m, 1H); 5.06 (dd, 1H); 4.43 (s, 1H); 7.58 (m, 2H); 7.70 (t, 1H); 8.01 (d, 2H); 8.20 (s, 1H).
® x.
Example 23: 12-(dimethylamino)-3,8-dimethyl-4,14-dioxo- 5,9,15-trioxatetracyclo[11.2.1.0%°.0%!*|hexadec-13(16)-en-1 1-yl acetate:
This compound is obtained by a procedure similar to that described for the synthesis of the compound of Example 17. The expected product is obtained in the form of a white powder.
NMR-'H (DMSO):1.14 (s, 3H); 1.26 (d, 3H); 1.94 (dd, 1H); 2.05 (t, 1H); 2.08 (s, 3H); 2.45 (s, 6H); 2.62 (t, 1H); 3.97 (m, 1H); 3.32 (m, 1H); 3.90 (d, 1H); 4.68 (m, 1H); 4.78 (m, 1H); 5.39 (s, 1H); 8.12 (s, 1H).
Example 24: 12-(dimethylamino)-3,8-dimethyl-4,14-dioxo-5,9,15- trioxatetracyclo[11.2.1.0%%.0*""|hexadec-13(16)-en-1 1-yl cyclohexanecarboxylate: ® This compound is obtained by a procedure similar to that described for the synthesis of the compound of Example 18. The expected product is obtained in the form of a white powder.
NMR-'H (DMSO): 1.14 (s, 3H); 1.26 (d, 3H); 1.08-1.48 (m, 5H); 1.58 (m, 1H); 1.68 (m, 2H); 1.84 (1, 2H); 1.93 (dd, 1H); 2.03 (t, 1H); 2.37 (m, 1H); 2.44 (s, 6H); 2.61 (t, 1H); 2.98 (m, 1H); 3.32 (t, 1H); 3.87 (d, 1H); 4.66 (m, 1H); 4.77 (dd, 1H); 5.40 (s, 1H); 8.12 (s, 1H).
Example 25: 12-(dimethylamino)-3,8-dimethyl-4,14-dioxo-5,9,15- trioxatetracyclo[1 1.2.1.0%5.0*""Jhexadec-13(16)-en-11-yl 4-fluorobenzoate:
This compound is obtained by a procedure similar to that described for the synthesis of the compound of Example 18. The expected product is obtained in the form of a white powder. ® NMR-'H (DMSO): 1.20 (s, 3H); 1.28 (d, 3H); 1.97 (dd, 1H); 2.08 (t, 1H); 2.46 (s, 6H); 2.65 (t, 1H); 3.00 (m, 1H); 3.50 (d, 1H); 4.04 (d, 1H); 4.71 (m, 1H); 5.04 (dd, 1H); 5.43 (s, 1H); 7.41 (1, 2H); 8.06 (dd, 2H); 8.20 (s, 1H).
Example 26: 11-{[tert-butyl(dimethyl)silyl]oxy}-12-(dimethylamino)-3,8-dimethyl- 5,9,15-trioxatetracyclo[11.2.1.0%°.03'°|hexadec-13(16)-ene-4,14-dione hydrochloride:
A solution of hydrochloric acid (0.3 mmol; 0.3 ml; 1V in ether) is added to a solution of the compound of Example 16 (0.22 mmol; 100 mg) in acetone (2 ml). The precipitate is filtered, washed with a little acetone, with ether and dried under reduced pressure, 70mg of the expected product is obtained in the form of a white powder.
® 0
NMR-'H (DMSO): 0.14 (d, 6H); 0.90 (s, 9H); 1.15 (s, 3H); 1.27 (d, 3H); 1.85 (dd, 1H); 2.05 (t, 1H); 2.72 (t, 1H); 2.90-3.25 (m, 7H); 3.72 (m, 1H); 3.93 (m, 1H); 4.76 (m, 2H); 5.46 (s, 1H); 8.70 (d, 1H); 11.64 (s, 1H).
Example 27: 12-(dimethylamino)-3,8-dimethyl-4,14-dioxo- 5,9,15-trioxatetracyclo[11.2.1.0>°.0%'"|hexadec-13(16)-en-11-yl heptanoate:
This compound is obtained by a procedure similar to that described for the synthesis of the compound of Example 18. The expected product is obtained in the form of a white powder.
NMR-'H (DMSO): 0.86 (t, 3H); 1.14 (s, 3H); 1.20-1.35 (m, 9H); 1.55 (m, 2H); 1.95 (dd, 1H); 2.02 (t, 1H); 2.35 (t, 2H); 2.44 (s, 6H); 2.61 (t, 1H); 2.96 (m, 1H); 3.33 ® (t, 1H); 3.89 (d, 1H); 4.68 (m, 1H); 4.77 (dd, 1H); 5.40 (s, 1H); 8.12 (s, 1H).
Example 28: 12-(dimethylamino)-3,8-dimethyl-4,14-diox0-5,9,15- trioxatetracyclo[11.2.1.0>%.0*'*|hexadec-13(16)-en-11-yl 4-(trifluoromethyl)benzoate:
This compound is obtained by a procedure similar to that described for the synthesis of the compound of Example 18. The expected product is obtained in the form of a white powder.
NMR-'H (DMSO):1.21 (s, 3H); 1.28 (d, 3H); 2.01 (dd, 1H); 2.06 (t, 1H); 2.48 (s, 6H); 2.66 (t, 1H); 3.00 (m, 1H); 3.55 (d, 1H); 4.09 (d, 1H); 4.73 (m, 1H); 5.04 (dd, 1H); 5.44 (s, 1H); 7.96 (d, 2H); 8.19 (d, 2H); 8.21 (s, IH).
Example 29: 12-(dimethylamino)-3,8-dimethyl-4,14-diox0-5,9,15- ® trioxatetracyclo[1 1.2.1.0*%.0*"°|hexadec-13(16)-en-1 1-yl 2-thiophenecarboxylate:
This compound is obtained by a procedure similar to that described for the synthesis of the compound of Example 18. The expected product is obtained in the form of a white powder.
NMR-'H (DMSO): 1.20 (s, 3H); 1.27 (d, 3H): 1.99 (m, 1H); 2.07 (t, 1H); 2.49 (s, 6H); 2.65 (t, 1H); 3.00 (m, 1H); 3.47 (d, 1H); 4.00 (d, 1H); 4.70 (m, 1H); 5.01 (dd, 1H); 5.43 (s, 1H); 7.26 (t, 1H); 7.87 (d, 1H); 8.01 (dd, 1H); 8.18 (s, 1H).
Example 30: 12-(dimethylamino)-3,8-dimethyl-4,14-dioxo-5,9,15- trioxatetracyclo[11.2.1.0>°.0*"’|hexadec-13(16)-en-11-yl 3,3-dimethylbutanoate:
This compound is obtained by a procedure similar to that described for the synthesis of the compound of Example 18. The expected product is obtained in the form of a white powder.
® -31-
NMR-'H (DMSO): 1.00 (s, 9H): 1.15 (s. 3H): 1.26 (d. 3H); 1.94 (dd, 1H); 2.03 (t, 1H); 2.24 (dd, 2H); 2.45 (s, 6H); 2.62 (t, 1H); 2.98 (m, 1H); 3.32 (d, 1H); 3.86 (d, 1H); 4.65 (m, 1H); 4.81 (dd, 1H); 5.40 (s, 1H); 8.12 (s, 1H).
Example 31: 12-(dimethylamino)-3,8-dimethyl-4,14-diox0-5,9,15- trioxatetracyclo|1 1.2.1.0>5.0%'’| hexadec-13(16)-en-1 1-yl 1-benzothiophene-2- carboxylate:
This compound is obtained by a procedure similar to that described for the synthesis of the compound of Example 18. The expected product is obtained in the form of a white powder.
NMR-'H (DMSO): 1.22 (s, 3H); 1.28 (d, 3H); 2.01 (dd, 1H); 2.08 (m, lH); ( 2.50 (s, 6H); 2.66 (t, 1H); 3.00 (m, 1H); 3.52 (d, 1H); 4.05 (d, 1H); 4.71 (m, 1H); 5.06 (dd, 1H); 5.44 (s, 1H); 7.50 (t, 1H); 7.56 (t, 1H); 8.09 (t, 2H); 8.21 (s, 1H); 8.27 (s, 1H).
Example 32: 12-(dimethylamino)-3,8-dimethyl-4,14-dioxo- 5,9,15-trioxatetracyclo[11.2.1.0%.03'°|hexadec-13(16)-en-1 1-yl 2-furoate:
This compound is obtained by a procedure similar to that described for the synthesis of the compound of Example 18. The expected product is obtained in the form of a white powder.
NMR-'H (DMSO): 1.19 (s, 3H); 1.27 (d, 3H); 1.97 (dd, 1H); 2.07 (t, 1H); 2.47 (s, 6H); 2.64 (t, 1H); 3.00 (m, 1H); 3.46 (d, 1H); 4.00 (d, 1H); 4.70 (m, 1H); 4.98 (dd, 1H); 5.43 (s, 1H); 6.72 (d, 1H); 7.36 (d, 1H); 8.03 (s, 1H); 8.18 (s, 1H).
Example 33: 12-(dimethylamino)-3,8-dimethyl-4,14-dioxo- ® 5,9,15-trioxatetracyclo[11.2.1.0>%,0%°|hexadec-13(16)-en-1 1-yl S-nitro-2-furoate:
This compound is obtained by a procedure similar to that described for the synthesis of the compound of Example 18. The expected product is obtained in the form of a white powder.
NMR-'H (DMSO): 1.19 (s, 3H); 1.28 (d, 3H); 1.98 (dd, 1H); 2.08 (t, 1H), 2.45 (s, 6H); 2.64 (t, 1H); 3.00 (m, 1H); 3.53 (d, 1H); 4.08 (d, 1H); 4.72 (m, 1H); 4.97 (dd, 1H); 5.44 (s, 1H); 7.65 (d, 1H); 7.80 (d, 1H); 8.21 (s, 1H).
Example 34: 12-(dimethylamino)-3,8-dimethyl-4,14-dioxo0-5,9,15-trioxatetracyclo [11.2.1.0*°.0*""|hexadec-13(16)-en-1 1-yl 2-thiophenecarboxylate hydrochloride:
A solution of hydrochloric acid (0.8 mmol; 0.8 ml; 1N in ether) is added to a solution of the compound of Example 29 (0.44 mmol; 196 mg) in acetone (4 ml). The precipitate is
® ® aa filtered, washed with a little acetone, with ether and dried under reduced pressure. 180 mg of the expected product is obtained in the form of a white powder.
NMR-'H (DMSO): 1.23 (s, 3H); 1.29 (d, 3H); 1.90 (dd, 1H); 2.13 (t, 1H); 2.76 (t, 1H); 2.85-3.25 (m, 7H); 3.95 (m, 1H); 4.78 (m, 1H); 5.02 (m, 1H); 5.38 (m, LH); 5.51 (s, 1H); 7.29 (t, LH); 7.97 (s, 1H); 8.08 (d, 1H); 8.86 (s, 1H); 12.12 (s, 1H).
Example 35: 12-(dimethylamino)-3,8-dimethyl-4,14-diox0-5,9,15- trioxatetracyclo[1 1.2.1.0%%.0*'|hexadec-13(16)-en-1 1-yl 2-thienylacetate:
This compound is obtained by a procedure similar to that described for the synthesis of the compound of Example 18. The expected product is obtained in the form of a white ® powder.
NMR-'H (DMSO): 1.14 (s, 3H); 1.26 (d, 3H); 1.94 (dd, 1H); 2.04 (m, 1H); 2.38 (s, 6H); 2.61 (t, 1H); 2.97 (m, 1H); 3.37 (d, 1H); 3.88 (d, 1H); 4.00 (d, 2H); 4.68 (m, 1H); 4.78 (dd, 1H); 5.39 (s, 1H); 6.98 (m, 2H); 7.43 (d, 1H); 8.12 (s, 1H).
Example 36: 12-(dimethylamino)-3,8-dimethyl-4,14-diox0-5,9,15- trioxatetracyclo[11.2.1.0%°.0*'*|hexadec-13(16)-en-1 1-yl phenoxyacetate:
This compound is obtained by a procedure similar to that described for the synthesis of the compound of Example 18. The expected product is obtained in the form of a white powder.
NMR-'H (DMSO): 1.23 (s, 3H); 1.35 (d, 3H); 2.04 (dd, 1H); 2.13 (t, 1H); 2.58 (s, 6H); 2.67 (t, 1H); 3.06 (m, 1H); 3.48 (d, 1H); 4.08 (d, 1H); 4.77 (m, 1H); 4.86 (m, 1H); 4.96 (dd, 2H); 5.50 (s, 1H); 7.05 (m, 3H); 7.38 (m, 2H); 8.23 (s, 1H). ®
Example 37: 8-(dimethylamino)-3,10a-dimethyl-2,6-dioxodecahydro-4,7- methenofuro[3,2-cjoxireno[floxacycloundecin-9-yl 4-tert-butylphenylcarbamate: 4-terbutylphenylisocyanate (250 pmol; 44 mg) is added to a solution of the compound of Example 5 (200 umol; 67 mg) in 1,2-dichloroethane (10 ml). The solution obtained is stirred for 20 hours at 60 °C before evaporating the solvent under reduced pressure.
The residue is eluted on silica using a mixture of acetone and dichloromethane (20/80).
The residue is taken up in ether, filtered and dried under vacuum. 36 mg of product is obtained in the form of a white powder.
NMR-'H (DMSO): 1.18 (s, 3H); 1.25 (s, 9H); 1.27 (d, 3H); 1.95 (dd, 1H); 2.08 (t, 1H); 2.48 (s, 6H); 2.64 (t, 1H); 2.98 (m, 1H); 3.37 (m, 1H); 3.91 (d, 1H); 4.69
® ® -33- (m, 1H); 4.80 (dd, 1H); 5.40 (s, 1H); 7.29 (d, 2H); 7.38 (d, 2H); 8.12 (s, 1H); 9.67 (s, 1H).
Example 38: 8-(dimethylamino)-3,10a -dimethyl-2,6-dioxodecahydro-4,7- methenofuro|3,2-c]oxireno|f]oxacycloundecin-9-yl thien-2-ylcarbamate:
This compound is obtained by a procedure similar to that described for the synthesis of the compound of Example 18. The expected product is obtained in the form of a white powder.
NMR-'H (DMSO): 1.18 (s, 3H); 1.26 (d, 3H); 1.95 (m, 1H); 2.06 (m, 1H); 2.48 (s, 6H); 2.64 (t, 1H); 2.97 (m, 1H); 3.36 (m, 1H); 3.90 (m, 1H); 4.68 (m, 1H); 4.79 (m, 1H); 5.40 (s, 1H); 6.61 (s, 1H); 6.82 (s, 1H); 6.94 (s, 1H); 8.13 (s, 1H); 10.78 (s, ® 1H).
Example 39: 8-(dimethylamino)-3,10a -dimethyl-2,6-dioxodecahydro-4,7- methenofuro|3,2-cjoxireno[floxacycloundecin-9-yl 2-methoxyphenylcarbamate:
This compound is obtained by a procedure similar to that described for the synthesis of the compound of Example 18. The expected product is obtained in the form of a white powder.
NMR-'H (DMSO): 1.17 (s, 3H); 1.27 (d, 3H); 1.94 (dd, 1H); 2.05 (t, 1H); 2.48 (s, 6H); 2.63 (t, 1H); 2.98 (m, 1H); 3.37 (m, 1H); 3.80 (s, 3H); 3.87 (d, 1H); 4.68 (m, 1H); 4.80 (dd, 1H); 5.40 (s, 1H); 6.90 (t, 1H); 7.02 (d, 1H); 7.09 (t, 1H); 7.59 (d, 1H); 8.12 (s, 1H); 8.59 (s, 1H).
Example 40: 8-(dimethylamino)-3,10a -dimethyl-2,6-dioxodecahydro-4,7-metheno- ® furo[3,2-c]oxireno[floxacycloundecin-9-yl 2(methylthio)phenylcarbamate:
This compound is obtained by a procedure similar to that described for the synthesis of the compound of Example 18. The expected product is obtained in the form of a white powder.
NMR-'H (DMSO): 1.17 (s, 3H); 1.27 (d, 3H); 1.95 (dd, 1H); 2.08 (t, 1H); 2.40 (s, 3H); 2.48 (s, 6H); 2.63 (t, 1H); 2.98 (m, 1H); 3.37 (s, 1H); 3.84 (d, 1H); 4.67 (m, 1H); 4.80 (dd, 1H); 5.39 (s, 1H); 7.15-7.25 (m, 3H); 7.32 (t, 1H) 8.10 (s, 1H); 8.90 (s, 1H).
® -34-
Example 41: 8-(dimethylamino)-3,10a-dimethyl-2,6-dioxodecahydro-4,7- methenofuro[3,2-c]oxireno[f]loxacycloundecin-9-yl 2-ethoxyphenylcarbamate:
This compound is obtained by a procedure similar to that described for the synthesis of the compound of Example 18. The expected product is obtained in the form of a white powder.
NMR-'H (DMSO): 1.17 (s, 3H); 1.27 (d, 3H); 1.35 (t, 3H); 1.95 (dd, 1H); 2.05 (t, 1H); 2.48 (s, 6H); 2.63 (t, 1H); 2.98 (m, 1H); 3.34 (m, 1H); 3.90 (d, 1H); 4.07 (gq, 2H); 4.67 (m, 1H); 4.79 (dd, 1H); 5.40 (s, 1H); 6.90 (t, 1H); 7.01 (d, 1H); 7.07 (t, 1H); 7.58 (d, 1H); 8.12 (s, 1H); 8.46 (s, 1H).
Example 42: 8-(dimethylamino)-3,10a-dimethyl-2,6-dioxodecahydro-4,7- ® methenofuro[3,2-cJoxireno{floxacycloundecin-9-yl thien-3-ylcarbamate:
This compound is obtained by a procedure similar to that described for the synthesis of the compound of Example 18. The expected product is obtained in the form of a white powder.
NMR-'H (DMSO): 1.18 (s, 3H); 1.27 (d, 3H); 1.95 (dd, 1H); 2.05 (m, 1H); 2.48 (s, 6H); 2.64 (t, 1H); 2.98 (m, 1H); 3.36 (m, 1H); 3.90 (d, 1H); 4.68 (m, 1H); 4.80 (dd, 1H); 5.40 (s, 1H); 7.04 (d, 1H); 7.22 (s, 1H); 7.43 (t, 1H); 8.12 (s, 1H); 10.08 (s, 1H).
Example 43: 8-(dimethylamino)-3,10a-dimethyl-2,6-dioxodecahydro-4,7- methenofuro|3,2-cjoxireno[floxacycloundecin-9-yl 1-benzothien-3-ylcarbamate:
This compound is obtained by a procedure similar to that described for the synthesis of the compound of Example 18. The expected product is obtained in the form of a white powder. ® NMR-'H (DMSO): 1.20 (s, 3H); 1.28 (d, 3H); 1.98 (dd, 1H); 2.07 (m, 1H), 2.48 (s, 6H); 2.65 (t, 1H); 2.98 (m, 1H); 3.40 (m, 1H); 3.97 (d, 1H); 4.70 (m, 1H); 4.82 (dd, 1H); 5.40 (s, 1H); 7.40 (m, 2H); 7.65 (s, 1H); 7.95 (d, IH); 8.14 (m, 2H); 10.00 (s, 1H).
Example 44: 8-(dimethylamino)-3,10a -dimethyl-2,6-dioxodecahydro-4,7-metheno- furo[3,2-c]oxireno[f]oxacycloundecin-9-yl N-(ter-butoxycarbonyl)glycinate: 1-(3-dimethylaminopropyl)-3-ethylcarbodiimide hydrochloride (200 pmol; 38 mg), N- terbutyloxycarbonylglycine (200 pmol; 35mg), triethylamine (200 pmol; 28ul) and dimethylaminopyridine (10 umol; 3mg) are added to a solution of the compound of
Example 5 (200 pmol; 60 mg) in dichloromethane (5 ml). The solution is stirred for three hours at ambient temperature, poured into a solution of NaHCO; then extracted
® ® -35- with ethyl acetate. The organic phase is washed with water then with a saturated solution of sodium chloride before being dried over MgSO and filtered. The solvent is eliminated by distillation under reduced pressure. The residue is eluted on silica using a mixture of acetone and dichloromethane (40/60). The residue is taken up in ether, filtered and dried under vacuum. 25 mg of product is obtained in the form of a white powder.
NMR-'H (DMSO): 1.15 (s, 3H); 1.26 (d, 3H); 1.39 (s, 9H); 1.92 (dd, 1H); 2.05 (t, 1H); 2.43 (s, 6H); 2.62 (t, 1H); 2.98 (m, 1H); 3.35 (t, 1H); 3.75 (t, 2H); 3.84 (d, 1H); 4.67 (m, 1H); 4.81 (dd, 1H); 5.40 (s, 1H); 7.25 (t, 1H); 8.13 (s, 1H).
Example 45: 8-(dimethylamino)-3,10a -dimethyl-2,6-dioxodecahydro-4,7- methenofuro|3,2-c]oxireno|floxacycloundecin-9-yl thien-3-ylacetate: ® This compound is obtained by a procedure similar to that described for the synthesis of the compound of Example 44. The expected product is obtained in the form of a white powder.
NMR-'H (DMSO): 1.14 (s, 3H); 1.26 (d, 3H); 1.94 (dd, 1H); 2.05 (m, 1H); 2.37 (s, 6H); 2.61 (t, 1H); 2.97 (m, 1H); 3.33 (t, 1H); 3.77 (s, 2H); 3.88 (d, 1H); 4.67 (m, 1H); 4.78 (dd, 1H); 5.39 (s, 1H); 7.04 (d, 1H); 7.36 (s, 1H); 7.50 (t, 1H); 8.11 (s, LH).
Example 46: 8-(dimethylamino)-3,10a -dimethyl-2,6-dioxodecahydro-4,7- methenofuro[3,2-c]oxireno[f]oxacycloundecin-9-yl 1-benzothien-3-ylacetate:
This compound is obtained by a procedure similar to that described for the synthesis of the compound of Example 44. The expected product is obtained in the form of a white ( powder.
NMR-'H (DMSO): 1.13 (s, 3H); 1.25 (d, 3H); 1.94 (dd, 1H); 2.04 (t, 1H); 2.26 (s, 6H); 2.60 (t, 1H); 2.96 (m, 1H); 3.32 (m, 1H); 3.88 (d, 1H); 4.04 (s, 2H); 4.67 (m,1H); 4.74 (dd, 1H); 5.38 (s, 1H); 7.40 (m, 2H); 7.64 (s, 1H); 7.79 (d, 1H); 7.99 (d, 1H); 8.09 (s, 1H).
Example 47: 8-(dimethylamino)-3,10a -dimethyl-2,6-dioxodecahydro-4,7- methenofuro|3,2-c]oxireno[floxacycloundecin-9-yl thiophene-3-carboxylate:
This compound is obtained by a procedure similar to that described for the synthesis of the compound of Example 44. The expected product is obtained in the form of a white powder.
® ® -36-
NMR-'H (DMSO): 1.19 (s, 3H); 1.27 (d, 3H); 1.97 (dd, 1H); 2.07 (t, 1H); 2.48 (s, 6H); 2.65 (t, 1H); 2.99 (m, 1H); 3.46 (d, 1H); 3.98 (s, 1H); 4.70 (m, 1H); 5.02 (m, 1H); 5.43 (s, 1H); 7.49 (s, 1H); 7.69 (s, 1H); 8.18 (s, 1H); 8.40 (s, 1H).
Example 48: 8-(dimethylamino)-3,10a -dimethyl-2,6-dioxodecahydro-4,7- methenofuro|3,2-cloxireno[floxacycloundecin-9-yl S-phenylthien-2-ylcarbamate:
This compound is obtained by a procedure similar to that described for the synthesis of the compound of Example 37. The expected product is obtained in the form of a white powder.
NMR-'H (DMSO): 1.20 (s, 3H); 1.27 (d, 3H); 1.97 (dd, 1H); 2.03 (t, 1H); 2.38 (s, 6H); 2.67 (m, 1H); 2.98 (m, 1H); 3.37 (d, 1H); 3.94 (m, 1H); 4.69 (m, 1H), 4.81
C (m, 1H); 5.41 (s, 1H); 6.60 (s, 1H); 7.22 (m, 2H); 7.36 (t, 2H); 7.55 (d, 2H); 8.14 (s, 1H); 10.93 (s, 1H).
Example 49: 8-(dimethylamino)-3,10a -dimethyl-2,6-dioxodecahydro-4,7- methenofuro[3,2-c]oxireno[f]oxacycloundecin-9-yl 1-adamantylcarbamate:
This compound is obtained by a procedure similar to that described for the synthesis of the compound of Example 37. The expected product is obtained in the form of a white powder.
NMR-'H (DMSO): 1.14 (s, 3H); 1.26 (d, 3H); 1.60 (s, 6H); 1.80-1.94 (m, 6H); 1.94-2.09 (m, 4H); 2.47 (s, 6H); 2.62 (t, 1H); 2.96 (m, 1H); 3.21 (d, 1H); 3.38 (s, 1H); 3.76 (s, 1H); 4.64 (m, 2H); 5.37 (s, 1H); 6.96 (s, 1H); 8.05 (s, 1H).
Example 50: 8-(dimethylamino)-3,10a -dimethyl-2,6-dioxodecahydro-4,7- ® methenofuro[3,2-cloxireno[floxacycloundecin-9-yl 2-naphthylcarbamate:
This compound is obtained by a procedure similar to that described for the synthesis of the compound of Example 37. The expected product is obtained in the form of a white powder.
NMR-'H (DMSO): 1.20 (s, 3H); 1.28 (d, 3H); 1.96 (dd, 1H); 2.07 (t, 1H); 2.48 (s, 6H); 2.66 (t, 1H); 3.01 (m, 1H); 3.37 (m, 1H); 3.95 (d, 1H); 4.70 (m, 1H); 4.87 (dd, 1H); 5.42 (s, 1H); 7.38 (t, 1H); 7.46 (t, 1H); 7.55 (d, 1H); 7.82 (m, 3H); 8.10 (s, 1H); 8.14 (s, 1H); 10.01 (s, 1H).
o .
Example 51: 8-(dimethylamino)-3,10a -dimethyl-2,6-dioxodecahydro-4,7-metheno- furof3,2-cJoxireno[floxacycloundecin-9-yl 2-tert-butyl-6-methylphenylcarbamate:
This compound is obtained by a procedure similar to that described for the synthesis of the compound of Example 37. The expected product is obtained in the form of a white powder.
NMR-'H (DMSO): 1.14 (s, 3H); 1.20-1.42 (m, 12H); 1.92 (dd, 1H); 2.05 (m, 1H); 2.25 (s, 3H); 2.52 (s, 6H); 2.62 (m, 1H); 2.95 (m, 1H); 3.36 (m, 1H); 3.88 (m, 1H); 4.80-4.95 (m, 2H); 540 (s, 1H); 7.13 (m, 2H); 7.22 (s, 1H); 8.13 (s, 1H); 8.69 (s, 1H).
Example 52: 8-(dimethylamino)-3,10a -dimethyl-2,6-dioxodecahydro-4,7-metheno-
C furo[3,2-c]oxireno[fJoxa-cycloundecin-9-yl 2,5-dimethoxyphenylcarbamate:
This compound is obtained by a procedure similar to that described for the synthesis of the compound of Example 37. The expected product is obtained in the form of a white powder.
NMR-'H (DMSO): 1.17 (s, 3H); 1.27 (d, 3H); 1.94 (dd, 1H); 2.06 (m, 1H); 2.48 (s, 6H); 2.64 (t, LH); 2.98 (m, 1H); 3.33 (m, 1H); 3.69 (s, 3H); 3.76 (s, 3H); 3.89 (d, 1H); 4.68 (m, 1H); 4.80 (dd, 1H); 5.40 (s, 1H); 6.63 (d, 1H); 6.94 (d, 1H); 7.32 (s, 1H); 8.12 (s, 1H); 8.58 (s, 1H).
® 20 The usefulness of the compounds of the invention can be demonstrated in particular by the effect of a treatment with these compounds on: - the incorporation of cytosine labelled with >*P in a DNA fragment in the presence of
DNA polymerase of E. Coli (acellular system); - the incorporation of tritiated thymidine in the DNA of HT29 tumor cells in division over a period of 3 hours (cell system); and - the proliferation of two human cell lines Mia-Paca2 and DU145. 1) Procedures
Cell lines
® -38-
DU-145 (human prostate cancer cells), HT29 (cancer of the colon) and Mia-PaCa2 (human pancreatic cancer cells) were acquired from the American Tissue Culture
Collection (Rockville, Maryland, USA).
Incorporation of deoxycytidine 5 -[alpha® P]-triphosphate into a DNA in the presence of DNA polymerase in an acellular system
Labelling of the DNA is carried out on a DNA fragment which incorporates nucleotides by way of the activity of the DNA polymerase enzyme. From these nucleotides, the dCTP is labelled with radioactive phosphorus (?P).
Plasmidal DNA (pc DNA 3, invitrogen, Netherlands) is diluted to a concentration of 2 ng in 45 pl of TE solution (10 mM Tris-HCI, pH 8, mM EDTA) and denatured by ® heating to 100 °C for 10 minutes before being replaced directly in ice. The denatured
DNA is placed in the tube which contains the buffer solution of dATP, dGTP, dTTP, the Klenow DNA polymerase enzyme and the random primers (Rediprime II random prime labelling system, RPN 1633, RPN 1634, Amersham pharmacia biotech). 2 ul of
Redivue deoxycytidine 5’-[alpha*’P]-triphosphate (250 uCi specific activity
Amersham, Orsay, France) is added to start the reaction. The reaction is carried out in the presence or absence of the compound to be tested for 10 minutes at 37°. The reaction is stopped by adding 5 pl of EDTA (0.2M). The labelled DNA is recovered in 200 pl of isopropanol after centrifugation for 10 minutes at 12,000 rpm then washed with 70% ethanol. After drying completely, the DNA is solubilized in 50 pl of TE. 10 nL 1s counted in 5 ml of scintillator (Instagel plus and scintillation counter Packard,
Rungis, France). The results are expressed as a percentage of the inhibition of incorporation of the labelled nucleotide in the sample with respect to the control: 100 — [(DPM of the sample treated/ control DPM) x 100]. ® 25 Incorporation of thymidine labelled with tritium into DNA cells in exponential growth phase
HT29 cells are seeded in 96-well plates (culturPlate-96, Packard, Rungis, France) (4000 cells per well) with the medium (DME, Gibco BRL, Cergy-Pontoise, France) complemented with 10% of foetal calf serum, Gibco BRL, Cergy-Pontoise, France). On day 3, the medium is removed and replaced with medium containing the tritiated thymidine (5’-thymidine TRK.328, 1 mCi, 0.6 uCi/ well, Amersham, Orsay, France) with or without the compound. The treatments are carried out for 3 hours. The medium is then removed and the cells are washed twice with 200pl of PBS (Gibco BRL, Cergy-
Pontoise, France). The lysis solution (SDS 1.25%, EDTA 5 mM) is added for 10 minutes at ambient temperature, then 75 pl of scintillating liquid (microscint 40,
® a
Packard, Rungis, France) is added. The plates are read using Topcount (Packard,
Rungis, France). These tests are carried out in duplicate and the results are expressed with respect to the incorporation of the labelled nucleotide in the sample treated with the compound over the incorporation of the labelled nucleotide in the control sample (sample DPM / control DPM).
Measurement of cell proliferation
The cells placed in 80 pul of Dulbecco's modified Eagle medium (Gibco-BRL, Cergy-Pontoise, France) completed with 10% of foetal calf serum inactivated by heating (Gibco-BRL, Cergy-Pontoise, France), 50000 units/] of penicillin and 50 mg/l streptomycin (Gibco-BRL, Cergy-Pontoise, France), and 2 mM of ® glutamine (Gibco-BRL, Cergy-Pontoise, France) were seeded on a 96-well plate on day 0. The cells were treated on day 1 for 96 hours with increasing concentrations of each of the compounds to be tested. At the end of the of this period, quantification of the cell proliferation is evaluated by a colorimetric test based on the cleavage of the tetrazolium salt WST1 by mitochondrial dehydrogenases in viable cells leading to the formation of formazan (Boehringer Mannheim, Meylan, France). These tests are carried out in duplicate with 8 determinations per concentration tested. The products are solubilised in dimethylsulphoxide (DMSO) at 10° M and finally used in culture with 0.5% DMSO. 2) Results
Ata concentration of 100 pg/ml, the compound of Example 16, like dihydromikanolide, inhibits the activity of DNA polymerase in an acellular system (Table I). ® % inhibition of incorporation
Dihydromikanolide 77 +11
Example 16
Table 1
Moreover, the compound of Example 16, like dihydromikanolide, inhibits the incorporation of tritiated thymidine in the DNA of human HT29 cells (Table II).
® -40- sample dpm / control dpm
Concentration ng/ml 100 50 25
Dihydromikanolide 0.14 0.22 0.98
Example 16 0.52 0.58 0.71
Table Il
Finally, the compounds of Examples 1 to 3, 9, 16, 18, 22, 24 to 32 and 39 to 43 inhibit the proliferation of DU-145 cell lines with an ICs, inhibitory concentration lower than or equal to 30 uM, whereas the compounds of Examples 1 to 10, 12, 16 to 20, 22, 24 to ® 37 and 39 to 44 inhibit the proliferation of the Mia-Paca2 cell lines with an ICso inhibitory concentration lower than or equal to 30 pM.
Claims (4)
1. Compound of general formula (I) o Me L Pe ~ “0 ® oo Oo R, @ corresponding to general sub-formulae (I); and (I); R 3 0 Me 0 0 Me
R... Pe : OX 2 Oo o Oo 0 Oo 0] ® R, R (Ih (I: in which RR, represents a hydrogen atom or an SR4 or NR4R; radical; R; represents SR¢ or NRgR7. R; represents OH, O(CO)R 4, OSiR5R16R 17, O(CO)OR 3 or O(CO)NHR 5; Rs and Rg represent, independently, an alkyl radical, a cycloalkyl, cycloalkylalkyl, hydroxyalkyl radical or also one of the aryl or aralkyl radicals optionally substituted on
®
® a. their aryl group by one or more radicals chosen from the alkyl, hydroxy or alkoxy radicals, Rs and Ry represent, independently, a hydrogen atom, an alkyl radical, a cycloalkyl, cycloalkylalkyl, hydroxyalkyl radical or also one of the aryl or aralkyl radicals optionally substituted on their aryl group by one or more radicals chosen from the alkyl, hydroxy or alkoxy radicals, R4 and Rs being able to form together with the nitrogen atom which carries them a heterocycle with 5 to 7 members, the additional members being chosen from the -CRgRo-, -NRj¢-, -O- and -S- radicals, it being understood however that it there can only be one member chosen from -O- or -S- in said heterocycle, and Rg and Ry being able to form together with the nitrogen atom which carries them a heterocycle with 5 to 7 members, the additional members being chosen from the ® -CR1R 2, -NR3-, -O- and -S- radicals, it being understood however that there can only be one member chosen from -O- or -S- in said heterocycle, Rg, Ryo, Ryi and Ry3 represent, independently each time they are involved, a hydrogen atom or an alkyl, alkoxycarbonyl or aralkyl radical, Ry and Ri; representing, independently each time they are involved, a hydrogen atom or each of Ry and Rj; being able to form respectively together with Rg and Rj; an -O-(CH:;)>-O- radical attached on either side to the carbon atom which carries it, such a radical only being present however once at most per NR4R;5 or NRgR7 radical, represent, independently each time they are involved, a hydrogen atom or an alkyl radical; Ri4 represents an alkyl, cycloalkyl or adamantyl radical or one of the aryl, heteroaryl, aralkyl or heteroaralkyl radicals optionally substituted on their aryl or heteroaryl group by one or more radicals chosen from a halogen atom and the alkyl, haloalkyl, nitro, ® hydroxy, alkoxy, alkylthio or phenyl radicals; or also Rs is such that Rj4-COOH represents a natural amino acid or the optical enantiomer of such an amino acid; Ris, Rig and Ry; represent, independently, an alkyl radical or a phenyl radical; Rus represents an alkyl, cycloalkyl or adamantyl radical or one of the aryl, heteroaryl, aralkyl or heteroaralkyl radicals optionally substituted on their aryl or heteroaryl group by one or more radicals chosen from a halogen atom and the alkyl, haloalkyl, nitro, hydroxy, alkoxy, alkylthio or phenyl radicals; it being understood however that when the compounds correspond to general sub- formula (I)2, then R; does not represent a hydrogen atom;
® nN or a salt of a compound of general formula (I).
2. Compound according to claim 1, characterized in that it corresponds to general sub- formula (I) or is a salt of such a compound.
3. Compound according to claim 2, characterized in that: eR; represents a hydrogen atom or an NR4R; radical; e RR; representing an NR¢R7 radical. e Rjrepresents OH or an O(CO)R 4, OSiR sR ¢R 7 or O(CO)NHR ig radical.
®
4. Compound according to claim 1, characterized in that it corresponds to general sub- formula (I),.
5. Compound according to claim 1, characterized in that it is one of the following compounds: - 12-diisopropylaminomethyl-7-methyl-3,6,10,15-tetraoxapentacyclo
[12.2.1.0**.0°7.0>"*|heptadec-1(17)-ene-11, 16-dione; - 12-dimethylamino-3-dimethylaminomethyI-1 1 -hydroxy-8-methyl- 5,9,15-trioxatetracyclo[11.2.1 .028.0%'%Thexadec-1 3(16)-ene-4,14-dione; - 12-benzyl(methyl)amino-3-benzyl(methyl)aminomethyl-11-hydroxy-8-methyl- 5,9,15-trioxatetracyclo[11.2.1 .0%%.0%'%Jhexadec-1 3(16)-ene-4,14-dione; - 11-hydroxy-8-methyl-12-morpholino-3-morpholinomethyl- ® 5,9.15-trioxatetracyclo[11.2.1 07€.0%'""Thexadec-13( 16)-ene-4,14-dione; - 12-dimethylamino-11-hydroxy-3,8-dimethyl- 5,9,15-trioxatetracyclo[11.2.1.0*°.0*'°Jhexadec-13(16)-ene-4, 14-dione; - 11-hydroxy-3,8-dimethyl-12-(4-methylpiperidino)-
5.9,15-trioxatetracyclo[ 11.2.1 .0%6.0%'%Ihexadec- 13(16)-ene-4,14-dione; - 11-hydroxy-3,8-dimethyl-12-pyrrolidino- 5,9,15-trioxatetracyclo[11.2. 1.0%%.0*'%)hexadec-13(16)-ene-4, 14-dione; - ethyl 1-[11-hydroxy-3,8-dimethyl-4,14-dioxo- 5,9,15-trioxatetracyclo[11.2.1.0%¢.0*'*]hexadec-13(16)-en-12-yl]- 4-piperidinecarboxylate; - 12-(4-benzylpiperidino)-11-hydroxy-3,8-dimethyl- 5,9,15-trioxatetracyclo[11.2.1.07.0%'%|hexadec-13(16)-ene-4, 14-dione;
® a - 11-hydroxy-3,8-dimethyl-12-piperidino- 5,9,15-trioxatetracyclo[11.2.1.07°.0%!Jhexadec-13(16)-ene-4, 14-dione; - 12-(1,4-dioxa-8-azaspiro[4.5]dec-8-y1)-11-hydroxy-3,8-dimethyl- 5,9,15-trioxatetracyclo[11.2.1.0%°.0%!%Jhexadec-13(16)-ene-4, 14-dione; - 11-hydroxy-3,8-dimethyl-12-morpholino- 5,9,15-trioxatetracyclo[11.2.1.0%°.0%'*)hexadec-1 3(16)-ene-4,14-dione; - 11-(tert-butyldimethylsiloxy)-12-dimethylamino-3,8-dimethyl- ty y y y 5,9,15-trioxatetracyclo[11.2.1.0%°.0%'*hexadec-13(1 6)-ene-4,14-dione; - 3,8-dimethyl-12-(4-methylpiperidino)-4,14-dioxo- ylp 5,9,15-trioxatetracyclo[11.2.1.0%°.0%! “Thexadec-1 3(16)-en-11-yl acetate; ® - 3,8-dimethyl-12-(4-methylpiperidino)-4,14-dioxo-11-phenylcarbonyloxy- 5,9,15-trioxatetracyclo{11.2.1.0>°.0%'%|hexadec-13(16)-ene; - ethyl 3,8-dimethyl-12-(4-methylpiperidino)-4,14-dioxo- Y 5,9,15-trioxatetracyclo[11.2.1.0%°.0%'“Jhexadec-1 3(16)-en-11-yl carbonate; - 11-hydroxy-12-isobutylsulphanyl-3-isobutylsulphanylmethyl-8-methyl- 5,9,15-trioxatetracyclo[11.2.1.0° ©.0%Thexadec-13(1 6)-ene-4,14-dione; - 11-hydroxy-12-isobutylsulphanyl-3,8-dimethyl- P y 5,9,15-trioxatetracyclo[11.2.1.0%6.0%! Yhexadec- 13(16)-ene-4,14-dione; - 12-(dimethylamino)-3,8-dimethyl-4,14-dioxo-
5.9,15-trioxatetracyclo[11.2.1.02.6.08.10]hexadec-13(16)-en-11-yl benzoate; - 12-(dimethylamino)-3,8-dimethyl-4,14-dioxo- 5,9,15-trioxatetracyclo[11.2.1.02.6.08.10]hexadec-13(16)-en-11-yl acetate; @® - 12-(dimethylamino)-3,8-dimethyl-4,14-dioxo- 5,9,15-trioxatetracyclo[11.2.1 078.0" Jhexadec- 13(16)-en-11-yl cyclohexanecarboxylate; - 12-(dimethylamino)-3,8-dimethyl-4,14-dioxo- 5,9,15-trioxatetracyclo[11.2.1.07%.0*'“Thexadec-13(1 6)-en-11-yl 4-fluorobenzoate; - 12-(dimethylamino)-3,8-dimethyl-4,14-dioxo- 5,9,15-trioxatetracyclo[ 11.2.1 076.0%! Nhexadec-13(1 6)-en-11-yl heptanoate; - 12-(dimethylamino)-3,8-dimethyl-4,14-dioxo- 5,9,15-trioxatetracyclo[11.2.1.0°%.0*'Jhexadec-13(16)-en-11-yl 4- (trifluoromethyl)benzoate;
mn - 12-(dimethylamino)-3,8-dimethyl-4,14-dioxo-5,9,15- trioxatetracyclo[11.2.1 072.0%" hexadec- 13(16)-en-11-yl 2-thiophenecarboxylate; - 12-(dimethylamino)-3,8-dimethyl-4,14-dioxo-5,9,15- trioxatetracyclo[11.2.1.0*.0*'“|hexadec-13(16)-en-11-yl 3,3-dimethylbutanoate; -12-(dimethylamino)-3,8-dimethyl-4,14-diox0-5,9,15-
trioxatetracyclo[11.2.1.0%¢.0%!Jhexadec-13(16)-en-11 -yl 1-benzothiophene-2- carboxylate; - 12-(dimethylamino)-3,8-dimethyl-4,14-diox0-5,9,15- trioxatetracyclo[11.2.1 .0%%.0%!%hexadec- 13(16)-en-11-yl 2-furoate;
- 12-(dimethylamino)-3,8-dimethyl-4,14-diox0-5,9,15-
® trioxatetracyclo[11.2.1.0%%.0%'*Jhexadec-13(16)-en-11-yl 5-nitro-2-furoate;
- 12-(dimethylamino)-3,8-dimethyl-4, 14-dioxo- 3,9,15-trioxatetracyclo[11.2.1.02.6.08.10]hexadec-13(16)-en-11-yl 2-thienylacetate; - 12-(dimethylamino)-3,8-dimethyl-4, 14-dioxo-
5,9,15-trioxatetracyclo[11.2.1.02.6.08.10]hexadec-13(16)-en-11-yl phenoxyacetate; - 8-(dimethylamino)-3,10a-dimethyl-2,6-dioxodecahydro-4,7-methenofuro[3,2- cJoxireno[f]oxacycloundecin-9-yl 4-tert-butylphenylcarbamate;
- 8-(dimethylamino)-3,10a-dimethyl-2,6-dioxodecahydro-4,7-methenofuro[3,2- cJoxireno[fJoxacycloundecin-9-yl thien-2-ylcarbamate;
- 8-(dimethylamino)-3,10a-dimethyl-2,6-dioxodecahydro-4,7-methenofuro[3,2- cJoxireno[fJoxacycloundecin-9-yl 2-methoxyphenylcarbamate;
- 8-(dimethylamino)-3,10a-dimethyl-2,6-dioxodecahydro-4,7-metheno-furo[3,2- ® cloxireno[f]oxacycloundecin-9-yl 2(methylthio)phenylcarbamate; - 8-(dimethylamino)-3,10a-dimethyl-2,6-dioxodecahydro-4,7-methenofuro[3,2- cloxireno[f]oxacycloundecin-9-yl 2-ethoxyphenylcarbamate; - 8-(dimethylamino)-3,10a-dimethyl-2,6-dioxodecahydro-4,7-methenofuro(3,2- cloxireno[floxacycloundecin-9-yl thien-3-ylcarbamate; - 8-(dimethylamino)-3,10a-dimethyl-2,6-dioxodecahydro-4,7-methenofuro[3,2- cloxireno[fJoxacycloundecin-9-yl 1-benzothien-3-ylcarbamate;
- 8-(dimethylamino)-3,10a-dimethyl-2,6-dioxodecahydro-4,7-metheno-furo[3,2- cJoxireno[f]oxacycloundecin-9-yl N-(fer-butoxycarbonyl)glycinate; - 8-(dimethylamino)-3,10a-dimethyl-2,6-dioxodecahydro-4,7-methenofuro[3,2- c]oxireno[f]oxacycloundecin-9-yl thien-3-ylacetate;
® » - 8-(dimethylamino)-3,10a-dimethyl-2,6-dioxodecahydro-4,7-methenofuro(3,2- c]oxireno[f]oxacycloundecin-9-yl 1-benzothien-3-ylacetate; - 8-(dimethylamino)-3,10a-dimethyl-2,6-dioxodecahydro-4,7-methenofuro[3,2- c]oxireno[floxacycloundecin-9-yl thiophene-3-carboxylate; - 8-(dimethylamino)-3,10a-dimethyl-2,6-dioxodecahydro-4,7-methenofuro(3,2- cJoxireno(f]oxacycloundecin-9-yl 5-phenylthien-2-ylcarbamate; - 8-(dimethylamino)-3,10a-dimethyl-2,6-dioxodecahydro-4,7-methenofuro[3,2- c]oxireno[fJoxacycloundecin-9-yl 1-adamantylcarbamate; - 8-(dimethylamino)-3,10a-dimethyl-2,6-dioxodecahydro-4,7-methenofuro[3,2- cjoxireno[f]oxacycloundecin-9-yl 2-naphthylcarbamate; ® - 8-(dimethylamino)-3,10a-dimethyl-2,6-dioxodecahydro-4,7-metheno-furo[3,2- c]oxireno[fJoxacycloundecin-9-yl 2-zert-butyl-6-methylphenylcarbamate; - 8~(dimethylamino)-3,10a-dimethyl-2,6-dioxodecahydro-4,7-metheno-furo[3,2- cloxireno[f]oxacycloundecin-9-yl 2,5-dimethoxyphenylcarbamate; or a salt of one of the latter.
6. As a medicament, a compound of general formula (I) as defined in claim 1 or a pharmaceutically acceptable salt of the latter.
7. Medicament according to claim 6, characterized in that it is one of the following compounds: - 12-diisopropylaminomethyl-7-methyl-3,6,10,15-tetraoxapentacyclo ® [12.2.1.0%*.0°7.0"heptadec-1(17)-ene-11,16-dione; - 12-dimethylamino-3-dimethylaminomethyl-11-hydroxy-8-methyl- 5,9,15-trioxatetracyclo[ 11.2.1 .07°.0%'%hexadec-1 3(16)-ene-4,14-dione; - 12-benzyl(methyl)amino-3-benzyl(methyl)aminomethyl-11-hydroxy-8-methyl- 5,9,15-trioxatetracyclo[11.2.1 .02€.0%'%Jhexadec-1 3(16)-ene-4,14-dione; - 11-hydroxy-8-methyl-12-morpholino-3-morpholinomethyl- 5,9,15-trioxatetracyclo{11.2.1.0%%.0*'°Jhexadec-13(16)-ene-4,14-dione; - 12-dimethylamino-11-hydroxy-3,8-dimethyl- 5,9,15-trioxatetracyclo[11.2.1.0%%.0%'%Jhexadec-13(16)-ene-4, 14-dione; - 11-hydroxy-3,8-dimethyl-12-(4-methylpiperidino)- 5,9,15-trioxatetracyclo[ 11.2.1 076.0%" hexadec-1 3(16)-ene-4,14-dione;
® a - 11-hydroxy-3.8-dimethyl-12-pyrrolidino- 5,9,15-trioxatetracyclo[ 11.2.1.0%®.0%'°Jhexadec-13(16)-ene-4,14-dione; - ethyl 1-[11-hydroxy-3,8-dimethyl-4,14-dioxo- 5,9,15-trioxatetracyclo[11.2.1.0%.0*'“Jhexadec-13(16)-en-12-yl]- 4-piperidinecarboxylate; - 12-(4-benzylpiperidino)-11-hydroxy-3,8-dimethyl- 5,9,15-trioxatetracyclo[11.2.1 026,08! "hexadec-1 3(16)-ene-4,14-dione; - 11-hydroxy-3,8-dimethyl-12-piperidino- 5,9,15-trioxatetracyclo[11.2.1.0%°.0%°Jhexadec-13(16)-ene-4, 14-dione; -12-(1,4-dioxa-8-azaspiro[4.5]dec-8-yl)-11-hydroxy-3,8-dimethyl- ® 5,9,15-trioxatetracyclo[11.2.1 .0%%.0%'%lhexadec-1 3(16)-ene-4,14-dione; - 11-hydroxy-3,8-dimethyl-12-morpholino-
5.9,15-trioxatetracyclo[11.2.1.0%¢.0%" %hexadec- 13(16)-ene-4,14-dione; - 11-(tert-butyldimethylsiloxy)-12-dimethylamino-3,8-dimethyl- 5,9,15-trioxatetracyclo[11.2.1 .0%6.0*!"1hexadec-1 3(16)-ene-4,14-dione; - 3,8-dimethyl-12-(4-methylpiperidino)-4,14-dioxo- 5,9,15-trioxatetracyclo[11.2.1.0%°.0%!"Jhexadec-13(16)-en-11-yl acetate; - 3,8-dimethyl-12-(4-methylpiperidino)-4,14-dioxo-11-phenylcarbonyloxy- 5,9,15-trioxatetracyclo[11.2.1.0%¢.0%'*Jhexadec-13(16)-ene; - ethyl 3,8-dimethyl-12-(4-methylpiperidino)-4,14-dioxo- 5,9,15-trioxatetracyclo[ 11.2.1.0%.0%! %Thexadec-13(1 6)-en-11-ylcarbonate; - 11-hydroxy-12-isobutylsulphanyl-3-isobutylsulphanylmethyl-8-methyl-
® 5.9,15-trioxatetracyclo[11.2.1 07¢.0*!%hexadec- 13(16)-ene-4,14-dione; - 11-hydroxy-12-isobutylsulphanyl-3,8-dimethyl- 5,9,15-trioxatetracyclo[11.2.1 .0%6.0*'%hexadec-1 3(16)-ene-4,14-dione; - 12-(dimethylamino)-3,8-dimethyl-4,14-dioxo-
5.9,15-trioxatetracyclo[11.2.1.02.6.08.10Thexadec-13(16)-en-11-yl benzoate; - 12-(dimethylamino)-3,8-dimethyl-4,14-dioxo- 5,9,15-trioxatetracyclo[11.2.1.02.6.08.10]hexadec-13(16)-en-11-yl acetate; - 12-(dimethylamino)-3,8-dimethyl-4,14-dioxo- 5,9,15-trioxatetracyclo[ 11.2.1.0°%.0*'"*Jhexadec-13(16)-en-11-yl cyclohexanecarboxylate;
® " - 12-(dimethylamino)-3,8-dimethyl-4,14-dioxo- 5,9,15-trioxatetracyclo[11.2.1 .0%%.0%!% hexadec- 13(16)-en-11-yl 4-fluorobenzoate; - 12-(dimethylamino)-3,8-dimethyl-4,14-dioxo- 5,9,15-trioxatetracyclo[11.2.1.0>¢.0%! “Ihexadec- 13(16)-en-11-yl heptanoate;
-12-(dimethylamino)-3,8-dimethyl-4,14-dioxo- 5,9,15-trioxatetracyclo[11.2.1.0%°.0%'"Jhexadec-13(16)-en-11-yl 4- (trifluoromethyl)benzoate;
- 12-(dimethylamino)-3,8-dimethyl-4,14-dioxo-5,9,15- trioxatetracyclo[11.2.1 .07°.0%'*Ihexadec- 13(16)-en-11-yl 2-thiophenecarboxylate; - 12-(dimethylamino)-3,8-dimethyl-4,14-dioxo-5,9,15- ® trioxatetracyclo[11.2.1.0>%.0%'"|hexadec-13(16)-en-11-yl 3,3-dimethylbutanoate; - 12-(dimethylamino)-3,8-dimethyl-4,14-diox0-5,9,15- trioxatetracyclo[11.2.1.0°°,0%'*Jhexadec-13(16)-en-11-yl 1-benzothiophene-2- carboxylate;
- 12-(dimethylamino)-3,8-dimethyl-4,14-diox0-5,9,15- trioxatetracyclo[11.2.1.0%°.0%'*Jhexadec-13(16)-en-11-yl 2-furoate;
- 12-(dimethylamino)-3,8-dimethyl-4,14-diox0-5,9,15- trioxatetracyclo[11.2.1 02.08% hexadec-1 3(16)-en-11-yl 5-nitro-2-furoate; - 12-(dimethylamino)-3,8-dimethyl-4,14-dioxo-
5,9,15-trioxatetracyclo[11.2.1.02.6.08.10]hexadec-13(16)-en-11-yl 2-thienylacetate; - 12-(dimethylamino)-3,8-dimethyl-4,14-dioxo- 5,9,15-trioxatetracyclo[11.2.1.02.6.08.10]hexadec-13(16)-en-11-yl phenoxyacetate;
® - 8-(dimethylamino)-3.10a-dimethyl-2,6-dioxodecahydro-4,7-methenofuro[3,2- cJoxireno[fJoxacycloundecin-9-yl 4-tert-butylphenylcarbamate;
- 8-(dimethylamino)-3.10a-dimethyl-2,6-dioxodecahydro-4,7-methenofuro[3,2- cloxireno[f]oxacycloundecin-9-yl thien-2-ylcarbamate;
- 8-(dimethylamino)-3.10a-dimethyl-2,6-dioxodecahydro-4,7-methenofuro[3,2- cJoxireno[fJoxacycloundecin-9-yl 2-methoxyphenylcarbamate; - 8-(dimethylamino)-3.10a-dimethyl-2,6-dioxodecahydro-4,7-metheno-furo[3,2-
cJoxireno[f]oxacycloundecin-9-yl 2(methylthio)phenylcarbamate;
- 8-(dimethylamino)-3.10a-dimethyl-2,6-dioxodecahydro-4,7-methenofuro[3,2- cloxireno{fJoxacycloundecin-9-yl 2-ethoxyphenylcarbamate;
® Cw - 8-(dimethylamino)-3.10a-dimethyl-2,6-dioxodecahydro-4,7-methenofuro[3,2- cJoxireno[floxacycloundecin-9-yl thien-3-ylcarbamate; - 8-(dimethylamino)-3. 1 0a-dimethyl-2,6-dioxodecahydro-4,7-methenofuro[3,2- cJoxireno[floxacycloundecin-9-yl 1-benzothien-3-ylcarbamate; -8-(dimethylamino)-3.10a-dimethyl-2,6-dioxodecahydro-4,7-metheno-furo[3,2- cJoxireno[floxacycloundecin-9-yl N-(rer-butoxycarbonyl)glycinate; - 8-(dimethylamino)-3.10a-dimethyl-2,6-dioxodecahydro-4,7-methenofuro[3,2- cJoxireno[floxacycloundecin-9-yl thien-3-ylacetate; - 8-(dimethylamino)-3.10a-dimethyl-2,6-dioxodecahydro-4,7-methenofuro[3,2- cloxireno[fJoxacycloundecin-9-yl 1-benzothien-3-ylacetate; ® - 8-(dimethylamino)-3.10a-dimethyl-2,6-dioxodecahydro-4,7-methenofuro[3,2- cloxireno[floxacycloundecin-9-yl thiophene-3-carboxylate; - 8-(dimethylamino)-3.10a-dimethyl-2,6-dioxodecahydro-4,7-methenofuro[3,2- cJoxireno[fJoxacycloundecin-9-yl 5-phenylthien-2-ylcarbamate; - 8-(dimethylamino)-3.10a-dimethyl-2,6-dioxodecahydro-4,7-methenofuro[3,2- c]oxireno[floxacycloundecin-9-yl 1-adamantylcarbamate; - 8-(dimethylamino)-3.10a-dimethyl-2,6-dioxodecahydro- 4,7-methenofuro[3,2-cJoxireno[fJoxacycloundecin-9-yl 2-naphthylcarbamate; - 8-(dimethylamino)-3.10a-dimethyl-2,6-dioxodecahydro-4,7-metheno-furo[3,2- cloxireno[f]oxacycloundecin-9-yl 2-tert-butyl-6-methylphenylcarbamate; - 8-(dimethylamino)-3.10a-dimethyl-2,6-dioxodecahydro-4,7-metheno-furof3,2- ® cJoxireno[f]oxacycloundecin-9-yl 2,5-dimethoxyphenylcarbamate; or a pharmaceutically acceptable salt of one of the latter.
8. Pharmaceutical composition containing, as active ingredient, a compound of general formula (I) as defined in claim | or a pharmaceutically acceptable salt of the latter.
9. Pharmaceutical composition according to claim 8, characterized in that it contains, as active ingredient, one of the following compounds: - 12-diisopropylaminomethyl-7-methyl-3,6, 10,15-tetraoxapentacyclo
[12.2.1.0%*.0°7.0°" *Jheptadec-1(17)-ene-11, 16-dione; - 12-dimethylamino-3-dimethylaminomethyl-11-hydroxy-8-methyl- 5,9,15-trioxatetracyclo[11.2.1.0%¢.0*! “Thexadec-1 3(16)-ene-4,14-dione;
@® , - 12-benzyl(methyl)amino-3-benzyl(methyl)aminomethyl-11-hydroxy-8-methyl- 5,9,15-trioxatetracyclo[11.2.1.0%°.0%'“Jhexadec-13(16)-ene-4, 14-dione; - 11-hydroxy-8-methyl-12-morpholino-3-morpholinomethyl- 5,9,15-trioxatetracyclo[11.2.1 02.0" hexadec- 13(16)-ene-4,14-dione; -12-dimethylamino-11-hydroxy-3,8-dimethyl- 5,9,15-trioxatetracyclo[11.2.1.0%°.0*'*|hexadec-13(16)-ene-4, 14-dione; - 11-hydroxy-3,8-dimethyl-12-(4-methylpiperidino)- 5,9,15-trioxatetracyclo[11.2.1 .0%%.0%“hexadec-13(16)-ene-4, 14-dione; - 11-hydroxy-3,8-dimethyl-12-pyrrolidino- 5,9,15-trioxatetracyclo[11.2.1 .0%%.0%'"Thexadec- 13(16)-ene-4,14-dione; C - ethyl 1-[11-hydroxy-3,8-dimethyl-4,14-dioxo- 5,9,15-trioxatetracyclo[11.2.1.0%¢.0%! Yhexadec-13(16)-en-12-yl]- 4-piperidinecarboxylate; - 12-(4-benzylpiperidino)-11-hydroxy-3,8-dimethyl- 5,9,15-trioxatetracyclo[11.2.1 .0%¢.0%"%Thexadec- 13(16)-ene-4,14-dione; - 11-hydroxy-3,8-dimethyl-12-piperidino- 5,9,15-trioxatetracyclo[11.2.1 .07°.0%'%Thexadec- 13(16)-ene-4,14-dione; - 12-(1,4-dioxa-8-azaspiro[4.5]dec-8-yl)-11-hydroxy-3,8-dimethyl-
5,9.15-trioxatetracyclo[11.2.1 .026.0%%hexadec-1 3(16)-ene-4,14-dione; - 11-hydroxy-3,8-dimethyl-12-morpholino-
5.,9,15-trioxatetracyclo[11.2.1 07.0%" hexadec- 13(16)-ene-4,14-dione; - 11-(fert-butyldimethylsiloxy)-12-dimethylamino-3,8-dimethyl- ® 5,9,15-trioxatetracyclo[11.2.1 07°.0%'%Thexadec- 13(16)-ene-4,14-dione; - 3,8-dimethyl-12-(4-methylpiperidino)-4,14-dioxo- 5,9,15-trioxatetracyclo[11.2.1.0*°.0%'*Jhexadec-13(16)-en-11 -yl acetate; - 3,8-dimethyl-12-(4-methylpiperidino)-4,14-dioxo-11-phenylcarbonyloxy- 5,9,15-trioxatetracyclo[11.2.1 07.0%! %hexadec- 13(16)-ene; - ethyl 3,8-dimethyl-12-(4-methylpiperidino)-4,14-dioxo- 5,9,15-trioxatetracyclo[11.2.1 070.0% hexadec- 13(16)-en-11-yl carbonate; - 11-hydroxy-12-isobutylsulphanyl-3-isobutylsulphanylmethyl-8-methyl- 5,9,15-trioxatetracyclo[11.2.1 07.0%" hexadec- 13(16)-ene-4,14-dione; - 11-hydroxy-12-isobutylsulphanyl-3,8-dimethyl- 5,9,15-trioxatetracyclo[11.2.1.0%°.0%'%Jhexadec-13(16)-ene-4, 14-dione;
a - 12-(dimethylamino)-3,8-dimethyl-4,14-dioxo- 5,9,15-trioxatetracyclo[11.2.1.02.6.08.10]hexadec-13(16)-en-11-yl benzoate; - 12-(dimethylamino)-3,8-dimethyl-4,14-dioxo-
5.,9,15-trioxatetracyclo[11.2.1.02.6.08.10]hexadec-13(16)-en-11-yl acetate; -12-(dimethylamino)-3,8-dimethyl-4,14-dioxo-
5.9,15-trioxatetracyclo[11.2.1.0%°.0%'“Jhexadec-13(16)-en-11-yl cyclohexanecarboxylate; - 12-(dimethylamino)-3,8-dimethyl-4,14-dioxo- 5,9,15-trioxatetracyclo[11.2.1 .0%.0*'""Ihexadec- 13(16)-en-11-yl 4-fluorobenzoate; - 12-(dimethylamino)-3,8-dimethyl-4,14-dioxo- ) 5,9,15-trioxatetracyclo[11.2.1.0%¢.0%" Yhexadec-1 3(16)-en-11-yl heptanoate; - 12-(dimethylamino)-3,8-dimethyl-4,14-dioxo- 5,9,15-trioxatetracyclo[11.2.1 .0%6.0%'%hexadec- 13(16)-en-11-yl 4- (trifluoromethyl)benzoate; - 12-(dimethylamino)-3,8-dimethyl-4,14-dioxo0-5,9,15- trioxatetracyclo[11.2.1 028.0%" hexadec-1 3(16)-en-11-yl 2-thiophenecarboxylate; - 12-(dimethylamino)-3,8-dimethyl-4,14-dioxo-5,9,15- trioxatetracyclo[11.2.1.0%°.0%'|hexadec-13 (16)-en-11-yl 3,3-dimethylbutanoate; - 12-(dimethylamino)-3,8-dimethyl-4,14-diox0-5,9,15- trioxatetracyclo[11.2.1.0*%.0%'%Jhexadec-13(l 6)-en-11-yl 1-benzothiophene-2- carboxylate; - 12-(dimethylamino)-3,8-dimethyl-4,14-dioxo-5,9,15- C trioxatetracyclo[11.2.1.0%%.0%'“Jhexadec-1 3(16)-en-11-yl 2-furoate; - 12-(dimethylamino)-3,8-dimethyl-4,14-diox0-5,9,15- trioxatetracyclo[11.2.1 078.0% hexadec-1 3(16)-en-11-yl 5-nitro-2-furoate; - 12-(dimethylamino)-3,8-dimethyl-4,14-dioxo- 5,9,15-trioxatetracyclo[11.2.1.02.6.08.10]hexadec-13(16)-en-11-yl 2-thienylacetate; - 12-(dimethylamino)-3,8-dimethyl-4,14-dioxo- 5,9,15-trioxatetracyclo[11.2.1.02.6.08.10]hexadec-13(16)-en-11-yl phenoxyacetate; - 8-(dimethylamino)-3,10a-dimethyl-2,6-dioxodecahydro-4,7-methenofuro[3,2- cJoxireno[fJoxacycloundecin-9-yl 4-tert-butylphenylcarbamate; - 8-(dimethylamino)-3,10a-dimethyl-2,6-dioxodecahydro-4,7-methenofuro[3,2- cJoxireno[fJoxacycloundecin-9-yl thien-2-ylcarbamate;
* . ‘y - 8-(dimethylamino)-3,10a-dimethyl-2,6-dioxodecahydro-4,7-methenofuro[3,2- cloxireno(f]oxacycloundecin-9-yl 2-methoxyphenylcarbamate; - 8-(dimethylamino)-3,10a-dimethyl-2,6-dioxodecahydro-4,7-metheno-furo[3,2- cloxireno[floxacycloundecin-9-yl 2(methylthio)phenylcarbamate; - 8-(dimethylamino)-3,10a-dimethyl-2,6-dioxodecahydro-4,7-methenofuro[3,2- c]oxireno[fJoxacycloundecin-9-yl 2-ethoxyphenylcarbamate; - 8-(dimethylamino)-3,10a-dimethyl-2,6-dioxodecahydro-4,7-methenofuro(3,2- cloxireno[fJoxacycloundecin-9-yl thien-3-ylcarbamate; - 8-(dimethylamino)-3,10a-dimethyl-2,6-dioxodecahydro-4,7-methenofuro[3,2- cJoxireno[fJoxacycloundecin-9-yl 1-benzothien-3-ylcarbamate; o - 8-(dimethylamino)-3,10a-dimethyl-2,6-dioxodecahydro-4,7-metheno-furo[3,2- cloxireno[fJoxacycloundecin-9-yl N-(ter-butoxycarbonyl)glycinate; - 8-(dimethylamino)-3,10a-dimethyl-2,6-dioxodecahydro-4,7-methenofuro[3,2- cJoxireno[floxacycloundecin-9-yl thien-3-ylacetate; - 8-(dimethylamino)-3,10a-dimethyl-2,6-dioxodecahydro-4,7-methenofuro[3,2- cJoxireno[f]oxacycloundecin-9-yl 1-benzothien-3-ylacetate; - 8-(dimethylamino)-3,10a-dimethyl-2,6-dioxodecahydro-4,7-methenofuro[3,2- cJoxireno[f]oxacycloundecin-9-yl thiophene-3-carboxylate; - 8-(dimethylamino)-3,10a-dimethyl-2,6-dioxodecahydro-4,7-methenofuro[3,2- cloxireno[floxacycloundecin-9-yl 5-phenylthien-2-ylcarbamate; - 8-(dimethylamino)-3,10a-dimethyl-2,6-dioxodecahydro-4,7-methenofuro[3,2- cloxireno{f]oxacycloundecin-9-yl 1-adamantylcarbamate; ® - 8-(dimethylamino)-3,10a-dimethyl-2,6-dioxodecahydro-4,7-methenofuro[3,2- cjoxireno[f]oxacycloundecin-9-yl 2-naphthylcarbamate; - 8-(dimethylamino)-3,10a-dimethyl-2,6-dioxodecahydro-4,7-metheno-furo[3,2- cJoxireno[f]oxacycloundecin-9-yl 2-fers-butyl-6-methylphenylcarbamate; - 8-(dimethylamino)-3,10a-dimethyl-2,6-dioxodecahydro-4,7-metheno-furo[3,2- cJoxireno[floxacycloundecin-9-yl 2,5-dimethoxyphenylcarbamate; or a pharmaceutically acceptable salt of one of the latter.
10. Use of a compound of general formula (I) as defined in claim 1 or a pharmaceutically acceptable salt of the latter for preparing a medicament intended to inhibit DNA polymerases.
«oo , ; A _ -53- PCT/FR02/00092
11. Use of a compound of general formula (I) as defined in claim 1 or a pharmaceutically acceptable salt of the latter for preparing a medicament intended to treat diseases due to abnormal cell proliferation.
12. Use according to claim 11, characterized in that the disease due to abnormal cell proliferation is cancer.
13. Use according to claim 11, characterized in that the disease due to abnormal cell proliferation is chosen from atherosclerosis, benign hyperplasia of the prostate and fibroses.
14. Use of a compound of general formula (I) as defined in claim 1 or a pharmaceutically acceptable salt of the latter for preparing a medicament intended to treat viral diseases.
15. Use of a compound of general formula (I) as defined in claim 1 or a pharmaceutically acceptable salt of the latter for preparing a medicament intended to treat parasitic diseases.
16. Use of a compound of general formula (I) as defined in claim 1 or a pharmaceutically acceptable salt of the latter for preparing a medicament intended to treat diseases of bacterial origin.
17. A substance or composition for use in a method of inhibiting DNA polymerases, said substance or composition comprising a compound of general formula (I) as defined in claim 1 or a pharmaceutically acceptable salt of the latter, and said method comprising administering said substance or composition.
18. A substance or composition for use in a method of treating diseases due to abnormal cell proliferation, said substance or composition comprising a compound of AMENDED SHEET
- LY) z ( J -54- PCT/FR02/00092 general formula (I) as defined in claim 1 or a pharmaceutically acceptable salt of the latter, and said method comprising administering said substance or composition.
19. A substance or composition for use in a method of treatment according to claim 18, characterized in that the disease due to abnormal cell proliferation is cancer.
20. A substance or composition for use in a method of treatment according to claim 18, characterized in that the disease due to abnormal cell proliferation is chosen from atherosclerosis, benign hyperplasia of the prostate and fibrosis.
21. A substance or composition for use in a method of treating viral diseases, said substance or composition comprising a compound of general formula (I) as defined in claim 1 or a pharmaceutically acceptable salt of the latter, and said method comprising administering said substance or composition.
22. A substance or composition for use in a method of treating parasitic diseases, said substance or composition comprising a compound of general formula (I) as defined in claim 1 or a pharmaceutically acceptable salt of the latter, and said method comprising administering said substance or composition.
23. A substance or composition for use in a method of treating diseases of bacterial origin, said substance or composition comprising a compound of general formula (I) as defined in claim 1 or a pharmaceutically acceptable salt of the latter, and said method comprising administering said substance or composition.
24. A compound according to any one of claims 1 to 5, substantially as herein described and illustrated. -
25. A medicament according to claim 6, substantially as herein described and illustrated. AMENDED SHEET
~ 3 ¢ X ’
J . : v § -55- PCT/FR02/00092
26. A composition according to claim 8, substantially as herein described and illustrated.
27. Use according to any one of claims 10 to 16, substantially as herein described and illustrated.
28. A substance or composition for use in a method of treatment according to any one of claims 17 to 23, substantially as herein described and illustrated.
29. A new compound, a new medicament, a new composition, a new use of a compound as claimed in claim 1, or a substance or composition for a new use in a method of treatment, substantially as herein described. AMENDED SHEET
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
FR0100397A FR2819513B1 (en) | 2001-01-12 | 2001-01-12 | NOVEL MIKANOLIDE DERIVATIVES, THEIR PREPARATION AND THEIR THERAPEUTIC APPLICATIONS |
Publications (1)
Publication Number | Publication Date |
---|---|
ZA200305313B true ZA200305313B (en) | 2004-06-14 |
Family
ID=8858748
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
ZA200305313A ZA200305313B (en) | 2001-01-12 | 2003-07-09 | Mikanolide derivatives, their preparation and therapeutic uses. |
Country Status (6)
Country | Link |
---|---|
FR (1) | FR2819513B1 (en) |
HK (1) | HK1063793A1 (en) |
HU (1) | HUP0303873A3 (en) |
IL (1) | IL156593A0 (en) |
NO (1) | NO20033118L (en) |
ZA (1) | ZA200305313B (en) |
Family Cites Families (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
FR2801792B1 (en) * | 1999-12-01 | 2003-04-18 | Sod Conseils Rech Applic | A NEW MEDICINE, DIHYDROMIKANOLIDE, ITS PRODUCTION BY EXTRACTION OF THE PLANT MIKANIA MICRANTHA AND ITS USE AS ANTI-PROLIFERATIVE AGENT |
-
2001
- 2001-01-12 FR FR0100397A patent/FR2819513B1/en not_active Expired - Fee Related
-
2002
- 2002-01-11 IL IL15659302A patent/IL156593A0/en unknown
- 2002-01-11 HU HU0303873A patent/HUP0303873A3/en unknown
-
2003
- 2003-07-08 NO NO20033118A patent/NO20033118L/en not_active Application Discontinuation
- 2003-07-09 ZA ZA200305313A patent/ZA200305313B/en unknown
-
2004
- 2004-09-03 HK HK04106637A patent/HK1063793A1/en not_active IP Right Cessation
Also Published As
Publication number | Publication date |
---|---|
IL156593A0 (en) | 2004-01-04 |
NO20033118D0 (en) | 2003-07-08 |
NO20033118L (en) | 2003-07-11 |
FR2819513A1 (en) | 2002-07-19 |
HUP0303873A2 (en) | 2004-03-29 |
HK1063793A1 (en) | 2005-01-14 |
HUP0303873A3 (en) | 2005-02-28 |
FR2819513B1 (en) | 2005-06-17 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
KR20150014506A (en) | 7-Oxo-4,7-Dihydro-Pyrazolo[1,5-A]Pyrimidine Derivatives Which Are Useful in the Treatment, Amelioration or Prevention of a Viral Disease | |
KR20150009553A (en) | 7-Oxo-Thiazolopyridine Carbonic Acid Derivatives and Their Use in the Treatment, Amelioration or Prevention of a Viral Disease | |
US8318740B2 (en) | Compounds for protein kinase inhibition | |
KR20060015294A (en) | Pyrazolo-quinazoline derivatives, process for their preparation and their use as kinase inhibitors | |
TW201726678A (en) | Pyrimidone derivatives and their use in the treatment, amelioration or prevention of a viral disease | |
US20040138245A1 (en) | Product comprising mikanolide, dihydromikanolide or an analogue thereof combine with another anti-cancer agent for therapeutic use in cancer treatment | |
US9416143B2 (en) | Griseofulvin derivatives | |
US6887869B2 (en) | Mikanolide derivatives, their preparation and therapeutic uses | |
CA2983992A1 (en) | Polycyclic indoline and indolenine compounds | |
WO2018209239A1 (en) | Potent agelastatin derivatives as modulators for cancer invasion and metastasis | |
CA2473362A1 (en) | Substituted alkyl uracils and the use thereof | |
CN115109058B (en) | Medicine for treating gastric cancer and preparation method thereof | |
ZA200305313B (en) | Mikanolide derivatives, their preparation and therapeutic uses. | |
EP4387629A1 (en) | 6-substituted- and 6,7-disubstituted-7-deazapurine ribonucleoside analogues | |
WO2023030685A1 (en) | Novel ras inhibitors | |
DE602004003719T2 (en) | 9-AMINOPODOPHYL LOTOXINE DERIVATIVES, METHOD FOR THE PRODUCTION THEREOF AND PHARMACEUTICAL COMPOSITIONS CONTAINING SUCH DERIVATIVES | |
US6649618B2 (en) | Substituted amidoalkyl-uracils and their use | |
WO2017059401A2 (en) | Androgen receptor ligands | |
US8669248B1 (en) | Adenine inhibitors of HSP90 | |
EP1799686A1 (en) | Bioreductively-activated prodrugs | |
US7148253B2 (en) | 4-thio coumarins | |
CA2370066A1 (en) | Thiazolopyrimidines useful as tnf.alpha. inhibitors | |
NZ533747A (en) | New benzo[a]pyrano[3,2-h]acridin-7-one compounds, a process for their preparation and pharmaceutical compositions containing them | |
AU2006268743C1 (en) | 1- [2' , 3' -dideoxy-3' C- (hydroxymethyl) - beta-D-erythro-pentofuranosyl] cytosine derivatives as HIV inhibitors | |
AU2005247032A1 (en) | New benzo [b]pyrano[3,2-h]acridin-7-one cinnamate compounds, a process for their preparation and pharmaceutical compositions containing them |